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Abstract 
 
Nearly two-thirds of all disease-associated proteins are ‘undruggable’ by modern 
therapeutics, meaning they are inside cells, out of the reach of biologics, but lack small molecule 
binding pockets. Stabilized peptides have the potential to hit these targets, which would open a 
vast array of potential new therapies. One such target is the p53/MDM2 interaction—a protein-
protein interaction central to many cancers. Several inhibitors have been developed against the 
MDM2 protein because this target degrades the “the guardian of the genome” protein, p53. 
However, few of these peptides demonstrate the serum-independent, on-target efficacy required 
for clinical translation. In addition to having a strong target binding affinity, these peptides must 
efficiently penetrate the cell and evade proteolytic degradation. The design criteria for 
developing agents that can meet all of these requirements are still poorly understood. This work 
focuses on identifying the most important physicochemical properties that promote overall in 
vitro efficacy, taking into account the relevant molecular and cellular parameters in order to aid 
in future design of stabilized peptide therapeutics.    
The research presented here begins with measuring the effects that lipophilicity and 
charge have on have on cellular uptake as these are two commonly tuned parameters for 
promoting stabilized peptide efficacy. Furthermore, cellular membrane penetration is largely 
thought to be a major limiting factor for this class of drugs. Results showed that incremental 
increases in charge caused significant increases in uptake and that although lipophilic peptides 
are more efficient at entering cells than hydrophilic peptides, there is a point at which increased 
lipophilicity begins to instead decrease uptake (logD>~3.5). After obtaining these results, I 
 xiv 
moved on to selecting peptides discovered via bacterial surface display and measuring their 
binding affinities and in vitro efficacies as a precursor to a full physicochemical property profile 
in order to identify what the biggest contributors to efficacy are. After selecting those peptides, I 
measured their lipophilicities, cellular penetration rates, membrane interactions, and proteolytic 
stability. Ultimately, results showed that the cellular potency of this series of compounds appears 
to be driven by intracellular stability, which correlated with efficacy, rather than permeability, 
which did not at all correlate with efficacy. This was demonstrated by ATSP-7041, a promising 
MDM2/p53 inhibiting peptide and the only p53-based peptide that has led to a clinical lead 
compound, as well as pepC, a novel peptide with efficacy close to that of ATSP-7041. These two 
peptides showed the highest resistance to proteolytic degradation as well as the highest cellular 
potency, although ATSP-7041 had the slowest cellular uptake (~3-fold slower than pepC). 
Characterization of the molecules demonstrated they all had high affinity and modest membrane 
permeability, leading to stability as the differentiating factor. These results exhibit the need for a 
wholistic assessment of peptide properties to help inform efficacy outcomes and serve as a basis 
for future peptide development. 
 
 
 
 1 
Chapter 1 Introduction 
 
1.1 Dissertation Overview 
1.1.1 Objective 
The objective of this dissertation work was to elucidate the most important factors for achieving 
efficacy of stabilized peptide therapeutics. Using literature precedent as a starting point (Chapter 
1), we identified the physicochemical properties that drive traditional drug development, 
including size, lipophilicity and charge, and applied those principles to stabilized peptides that 
target the p53-MDM2 interaction. Using a series of novel stabilized peptides with high binding 
affinity to MDM2, we analyzed various physicochemical properties and determined which 
properties led to in vitro efficacy.  
1.1.2 Hypothesis 
Given that the guidelines set in place for traditional drug development (Lipinski’s Rule of Five) 
are intended to promote efficient cellular uptake, we hypothesized that efficacy would be uptake 
limited (given high target binding affinity in the single-digit nanomolar range). Much of our 
focus was therefore centered around the properties that affect uptake, such as lipophilicity and 
charge, and we hypothesized that those may be the most important determinants of efficacy. 
1.1.3 Work Plan  
In Chapter 2, we tested the effects that lipophilicity and charge have on cellular uptake and used 
a double-click stabilized MDM2-inhibiting peptide from literature as a proof-of-concept peptide. 
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This particular peptide, though not having in vitro efficacy, has several carboxylic acid residues 
that allowed us to make amino acid substitutions with the uncharged analogues in order to create 
a series of differently charged peptides without making sweeping chemical changes to the 
sequence. Additionally, using various different fluorescent linkers, we produced a series of 
peptides with varying lipophilicities and used fluorescence as a means to quantify uptake.  
 Chapter 3 will focus on characterizing a set of novel MDM2-inhibiting peptides 
discovered via bacterial surface display and selecting potential peptide drug candidates for 
further studies. The selection criteria will be based on target binding affinity and in vitro 
efficacy. 
 In Chapter 4, the peptides chosen for further study are profiled for physicochemical 
properties including lipophilicity, cellular uptake rate, membrane interactions, and protease 
stability. Based on the results, we determine that contrary to our hypothesis, the property that 
correlates best with efficacy for this peptide series is protease stability, not cellular uptake rate. 
Based on the high affinity and moderate permeability of these peptides, this highlights 
differences in protease stability, even within stapled peptide sequences, as critical for cell 
efficacy. 
 Chapter 5 will summarize all the work presented as well as offer ideas for future work to 
be done that can further elucidate the most important factors in peptide drug design.    
1.2 Publication Information 
L. Atangcho, T. Navaratna, G.M. Thurber. Hitting Undruggable Targets: Viewing Stabilized 
Peptides Through the Lens of Quantitative Systems Pharmacology. Trends in Biochemical 
Sciences. 44(3): 241-257 (2019). 
This publication has been modified to adapt to the content of this dissertation. 
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1.3 Abstract 
Stabilized peptide-based therapeutics have the potential to hit currently undruggable targets, 
dramatically expanding the druggable genome. However, major obstacles to their development 
include poor intracellular delivery, rapid degradation, low target affinity, and membrane toxicity. 
With the emergence of multiple stabilization techniques and screening technologies, many groups 
have demonstrated high efficacy of various bioactive peptides in vitro. However, fewer molecules 
have exhibited success in vivo. Here we discuss the chemical and pharmacokinetic barriers to 
achieving in vivo efficacy. Given their small size relative to traditional biologics, the molecular 
properties of stabilized peptides must be considered in a simultaneous and comprehensive manner 
in order to achieve the necessary rates for in vivo delivery to the target, efficacy, and ultimately, 
clinical translation.  
1.4 Opportunities and Challenges in the Peptide Drug Landscape 
The field of peptide therapeutics has come a long way from utilizing unmodified naturally 
occurring peptides as in the case of insulin therapy discovered in the early 20th century. Today, 
over 60 peptide-based therapeutic agents have been approved by the FDA and many more are in 
the drug development pipeline. The majority of these peptide drugs are analogs of previously 
discovered endogenous peptides, many of which target G-protein coupled receptors or other cell 
surface receptors with endogenous protein ligands1. These receptors, however, make up only a 
fraction of molecular targets to treat disease. Targeting other protein-protein interactions (PPIs) 
has proven to be a much larger challenge since most of them occur inside the cell, out of the 
reach of traditional biologics such as monoclonal antibodies. 
Currently, intracellular targeted therapeutics are dominated by lipophilic small molecule 
drugs that bind ‘druggable’ proteins that contain a small, hydrophobic binding pocket or enzyme 
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active site. However, the majority of disease-associated proteins lack such features2. In contrast, 
62% of PPIs have an alpha-helical motif in their binding interfaces3, and alpha helix-based 
surrogate peptide structures are able to disrupt the much larger (1000-2000Å2) binding interfaces 
between proteins4. Therefore, alpha helices are being explored for targeting these PPIs. In 
principle, alpha helical peptide scaffolds are an attractive drug class for targeting PPIs due to 
their balanced size: large enough to specifically disrupt PPIs like biologics but compact enough 
to enter cells like small molecules. However, without modification, they suffer from rapid 
degradation, fast clearance, low to insufficient membrane permeability, and poor target affinity. 
Over the past two decades and continuing with current research, the barriers to 
intracellular delivery of alpha helix scaffolds are slowly being eroded with the emergence of 
helix stabilization chemistries, modification of peptide physicochemical properties, and 
screening technologies to select stand-alone high affinity agents, which is a challenge given the 
much larger chemical space of macromolecular drugs. Helix stabilization approaches (Fig. 1.1) 
help decrease degradation rates and potentially increase target affinities5,6. Several groups have 
O NH HN O S S
O O
N
N
N N
N
NLinker
S S
Figure 1.1 Peptide Stabilization Techniques A (non-exhaustive) representation of several 
reported peptide staples is shown. All examples are drawn as i,i+4 staples except the last which 
is shown as i,i+7, a more common stapling position for that staple type. From left to right, lactam 
bridge, disulfide bridge, bis-alkylation of cysteine residues, ring-closing olefin metathesis of O-
allylserine residues, all-hydrocarbon staple via ring-closing metathesis of 𝛼, 𝛼-disubstituted non-
natural amino acids with all-hydrocarbon side chains, double-click stabilization of azido non-
natural amino acids. 
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since adopted these techniques to engineer novel therapeutic and diagnostic constrained alpha 
helices with targets spanning a variety of human diseases. Combined with the development of 
various peptide library screening methods (phage, mRNA and bacterial display)7,8, these 
advances have propelled the field forward, and some agents have entered clinical trials9. Until 
one or more FDA approved drugs are developed, it remains unclear whether alpha helices are 
generally suitable for targeting intracellular PPIs. However, multiple approaches have been 
explored for overcoming the intrinsic challenges in developing these agents, and significant 
progress is being made10. Here, we focus on the quantitative pharmacology aspects of stabilized 
peptides, where multiple properties must be considered simultaneously for translational 
development. 
This overview will focus on the need for a ‘systems’ approach to stabilized peptide 
scaffold development, where changes in one property impact the distribution of the agent across 
multiple length and time scales within a living organism. In early stages of development, beyond 
measuring target binging affinities, groups typically establish the efficacy of their peptides via in 
vitro cellular assays such as cell killing and gene reporter assays. Many also perform imaging of 
fluorophore-conjugated variants to demonstrate cellular uptake (intracellular targets) or cell 
surface binding (extracellular targets) as well as immunoprecipitation and western blotting to 
show up or downregulation of native proteins. Much of the development work at this stage is 
carried out in cell culture, and this makes sense from the standpoint that the most formidable 
barrier to development of macromolecular agents that bind intracellular targets is accessing the 
cytosol. However, there are far fewer reports of in vivo efficacy studies, the precursor to clinical 
trials, and some of the strategies and mechanisms employed in cells may have deleterious effects 
in the context of an animal model or patient. Furthermore, various studies have revealed 
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uncertainties in how effectively some of these recently developed peptides penetrate cells and 
bind their targets11,12. Efficient cell membrane permeability is just one of many variables to 
consider for successful in vivo drug delivery. Ultimately, stabilized peptide design must be 
focused on reaching systemic circulation (following various routes of administration), remaining 
in circulation for extended periods of time (delayed renal and/or hepatic clearance), evading 
protease degradation (systemic and local degradation/‘clearance’), reaching target organs and 
distributing in the tissue, penetrating cell membranes for intracellular targets, reaching the 
subcellular location (e.g. nuclear targets), and binding tightly to the target (Fig. 1.2). In this 
review, we examine various classes of constrained peptides that have exhibited robust 
pharmacokinetics for clinical translation from a quantitative systems pharmacology view and 
examine them in comparison to stabilized peptides specifically. 
1.5 Stabilized Alpha Helices as a Peptide Drug Scaffold 
It has long been recognized that more rigid/constrained molecules have the potential for 
higher binding affinity (see Box 1.1 on helicity), and the alpha helix, one of the most prevalent 
Figure 1.2 Multiscale Pharmacokinetic Challenges of Therapeutic Peptides 
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secondary structures in proteins, has many attractive properties as a scaffold. The pursuit of 
structurally locking alpha helices in their conformation began several decades ago. Early 
techniques included the use of disulfide and lactam bridges (Fig. 1.1) as well as metal ion 
complexes. In 2000, Schafmeister and Verdine published an all-hydrocarbon stapling method 
adapted from a previously published ring-closing olefin metathesis stapling method by Blackwell 
and Grubbs13 (Fig. 1.1). These peptides showed increased helicity and proteolytic stability14 and 
created significant excitement within the field. By incorporating terminal alkene-functionalized 
non-natural amino acids with varying chain lengths, R and S stoichiometries to account for 
stereochemistry effects, and placing the reactive residues in i, i+4 and i, i+7 locations of the 
peptide, they optimized their stapling method to efficiently stabilize the scaffold15. This all-
hydrocarbon stapling technique was first tested by Walensky and colleagues, who designed 
peptides after the BH3 domain of a BCL-2-member protein, stabilized these peptides using their 
all-hydrocarbon stapling technique, and showed that the peptides were able to bind pro-apoptotic 
proteins and cause apoptosis of cancer cells in vitro and in vivo5. Similarly, Bernal and 
colleagues, also from the Verdine group, tested their stabilization technique on p53-based 
peptides. P53 is a transcription factor that regulates cell growth and apoptosis as a response to 
DNA damage and cellular stress. Its activity is regulated by MDM2, an E3 ubiquitin ligase that 
marks p53 for degradation when its functions are not necessary. Loss of p53 activity is the most 
common deficiency in human cancer, whether due to mutation of the gene or due to 
overexpression of MDM216.  Bernal et al. designed several p53-based peptides and showed that 
one of their variants, p53-SAH-8, had a higher binding affinity for MDM2 (Kd=55nM) than the 
wild-type p53 (Kd=410nM). They also demonstrated in vitro cell permeability, which caused 
apparent upregulation of native p53—reactivating the apoptotic pathway17. 
 8 
The Verdine group took some of the first steps toward the design of stapled peptides with 
intracellular therapeutic effects that overcome several barriers associated with delivery of 
peptides. However, particularly in these early days, the slow throughput in synthesizing 
individual peptide sequences and testing for cell permeability combined with the gap in 
knowledge around the pharmacokinetic properties of molecules in this size range made progress 
arduous. Since this time, high throughput screening methods combined with novel chemistry 
have allowed isolation of high affinity sequences, aiding this step in development18–20. Recently, 
Lau and colleagues designed a p53-based peptide for therapeutic modulation of the p53-MDM2 
interaction using two bioorthogonal reactions (an approach first reported by Torres and 
colleagues21). Instead of cross reacting two complementary residues, they placed two azido-
functionalized residues in i, i+7 locations and stapled the peptide with a di-alkyne linker by 
copper-catalyzed azide-alkyne cycloaddition—a well characterized click chemistry reaction22 
(Fig. 1.1). This strategy, termed “double-click stabilization,”23 conveniently allows the 
introduction of additional functionality on the linker (e.g. modification of charge, lipophilicity, 
imaging tag incorporation, etc.)6,24. In addition to modifying the physicochemical properties of 
peptides, these polyfunctional linkers can contribute to protease stability and binding affinity 
through reducing the entropic penalty of binding and through direct (enthalpy) contributions 
(Box 1.1). 
Stapling techniques allow for added complexity in peptide drug design, giving more 
nuanced control over the properties one can change to help achieve desired peptide outcomes. 
Despite these advances in peptide chemistry and molecular engineering, the field of constrained 
peptides still faces formidable challenges, particularly in the delivery of these agents to the site 
of action, which will need to be overcome to gain widespread clinical relevance. Now that more 
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tools are becoming available to generate defined molecular properties, the major question 
remains: what properties are needed for clinically translatable drugs? 
Stabilized peptide scaffolds sit at the interface of biologics and small molecule drugs, and 
guidance for development can be found in both fields. Several of the high throughput approaches 
have taken advantage of directed evolution from the field of biologics to screen a billion or more 
(109 to 1012) variants. (For comparison, a 12-mer peptide with only natural amino acids has a 
sequence space of 2012 ~ 4x1015 unique sequences.) To access the cytosol, where many relevant 
protein-protein interactions occur, inspiration can be found in the world of small molecules. 
 
1.6 Non-Lipinksi Drugs: Cyclic Peptides and Related Macrocycles 
Most drugs against intracellular targets are small molecules—a class of compounds containing 
molecules sharing a specific set of physicochemical properties summed up by Lipinski’s Rule of 
Five (Ro5)25. Imaging studies show that this class of agents can enter cells and reach their 
subcellular target within seconds to minutes26,27. Drugs that adhere to these guidelines tend to be 
well-absorbed making them good candidates for oral delivery. However, due to their small size 
(<500 Da), they lack large contact surface area for binding, making them prone to low specificity 
for their intended targets. Conversely, biologic drugs typically have molecular weights above 
5000 Dalton (e.g. antibodies). Though they boast high target specificities due to large contact 
surface areas for binding, they often require intravenous delivery (see Box 1.2) and lack 
intracellular access28. Peptides and other non-traditional (non-Ro5) drug molecules falling in 
between small molecules and biologics have the potential to provide the best of both worlds. 
Though stapled peptides have yet to be FDA-approved, other non-traditional drug types have 
been approved or are in clinical development. Among them are cyclic peptides, which compared 
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to all other peptide drugs have shown the highest abundance of orally bioavailable agents29. 
While oral bioavailability is distinct from intracellular delivery/cytosolic access, many oral drugs 
are absorbed through transcellular transport across the intestinal epithelium, so they share some 
stability and permeability characteristics. 
1.6.1 Physicochemical Properties 
What properties allow cyclic peptides to be well-absorbed? Nielsen and colleagues provide an 
exhaustive analysis of 125 orally bioavailable cyclic peptides and their properties, including 
molecular weight, predicted lipophilicity, and polar surface area. They profiled the properties of 
a variety of cyclic peptides with greater than four residues, including circular cysteine-knotted 
peptides, termed cyclotides, natural product cyclic peptide Cyclosporin A and its derivatives, 
and, for comparison sake, the doubly stapled alpha helix SAH-gp41(626-662)—the only stabilized 
alpha helix with reported oral bioavailability thus far (though percent oral bioavailability was 
never reported for this peptide). Nielsen examined the correlation between multiple 
physicochemical properties and oral bioavailability. First, a high molecular weight (>500 Da) did 
not appear to preclude oral bioavailability as it does in the case of small molecules. They found 
that even in the higher molecular weight range for the peptides analyzed (960-1350 Da), 23 
peptides had oral bioavailability greater than or equal to 10%, and lower molecular weight did 
not correlate with higher oral bioavailability29. This suggests that for peptides, other properties 
may be of greater importance when considering rates of drug absorption. Furthermore, upon 
comparing predicted octanol-water partition coefficients (logP, Box 1.3) as measured by 
Molinspiration cheminformatics or QikProp software, Nielsen et al. reports that the lipophilicity 
of orally bioavailable cyclic peptides tend to fall within Ro5 guidelines, 0≤LogP≤5, but that a 
slightly higher range of 0-8 (as calculated with Molinspiration) seemed permissible. 
 11 
Other original Ro5 properties include the number of hydrogen bond donors and 
acceptors, limited to less than 5 and 10, respectively25. Nielsen’s study found that cyclic peptides 
with greater than 6 hydrogen bond donors had oral bioavailability of less than 10%. However, 
the number of hydrogen bond acceptors, defined as simply the total number of nitrogen and 
oxygen atoms in the molecule, was greater than 10 for all cyclic peptides in the study, therefore 
not meeting the Ro5 criteria. A number of studies conclude that few rotatable bonds (no more 
than 10-13) corresponds to good oral bioavailability, likely due to a decrease in solvent 
interactions and lower susceptibility to degradation because of structural rigidity30,31. Cyclic 
peptides are advantaged in this area due to the fact that they are inherently constrained29. 
1.6.2 Backbone Modifications 
Many peptide macrocycles and other ‘Ro5 violators’ that have had success in the clinic are 
derived from natural products4. These peptides have been widely studied as models for synthetic 
derivatives or de novo cyclic peptides. Cyclosporin A, for example, is a naturally occurring 
orally bioavailable (oral bioavailability = 29%) 11-residue peptide macrocycle used as an 
immunosuppressant drug32. Despite definitively falling outside of Lipinksi’s standards for drug-
likeness, Cyclosporin A and other natural product macrocycles have the uncanny ability to 
traverse membranes, avoid degradation, and bind efficiently to their targets in their necessary 
conformations4,29,32,33. One of the common characteristics of natural product macrocycles like 
Cyclosporin A is amide N-methylation32,34,35. In a study of 39 peptide macrocycles by Ahlbach 
and colleagues, all compounds with measurable passive permeability except one had amide N-
methylation32. N-methylation has been widely shown to improve membrane permeability of 
natural product peptide macrocycle derivatives, a phenomenon attributed to a decrease in 
solvent-exposed polar groups (polar surface area), therefore reducing the desolvation energy 
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required for crossing membranes33–35. In addition, designing molecules to enable the formation 
of intramolecular hydrogen bonds and introducing sterically hindering hydrophobic groups also 
adds to these permeability enhancing effects32,36. This may be particularly important for 
imparting ‘chameleon’-like properties to maintain solubility: solvent hydrogen bonding in 
aqueous environments and intramolecular hydrogen bonding while crossing membranes4. These 
are all useful insights in the design of stabilized alpha helices since hydrogen bonding via staple 
choice and sequence optimization could prove useful for achieving enhanced permeability and in 
vivo efficacy. 
 
1.7 Stabilized Alpha Helices: Properties and Challenges 
1.7.1 Access to the Cytosol 
Membrane permeability of stabilized peptide structures is the most challenging step in delivery 
to the site of action (the target). After all, membrane partitioning is a basic element of a 
functioning cell. In recent years, elucidating the nuances of how peptides enter cells has been an 
increasingly active area of research in the field of stabilized peptides. Early methods of verifying 
cellular uptake included conjugating peptides to fluorophores, treating cells with the fluorophore-
conjugated peptides, and using microscopy or flow cytometry to detect intracellular 
fluorescence5,6,17,37,38. This is a challenging task, since care must be taken to distinguish cellular 
uptake in endosomes/lysosomes (which do not have access to cytosolic targets) versus 
localization in the cytosol itself. These methods however, do not directly measure target 
engagement. Even cell viability assays without the use of proper controls are at risk of false 
positives. This became clear with the emergence of methods directly assessing whether peptides 
have off-target toxicity11. Adopted from the viral and gene delivery fields, positive charge is one 
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method of conferring membrane permeability of peptides6,39,40. However, methods such as the 
recombinase enhanced bimolecular luciferase complementation platform (ReBiL) and LDH 
release quantification highlighted some of the toxicity hurdles inherent in cationic agents and 
motivated other strategies to achieve membrane permeability11,12. Just a few years since the first 
hydrocarbon stapled peptides were introduced, researchers in the field are developing new 
membrane permeable peptides with more robust methods of demonstrating on-target efficacy 
using in vitro assays and giving special attention to physicochemical properties outside of charge 
that can help improve cytosolic delivery41–44. However, careful consideration of drug delivery 
issues outside of the cellular challenges, including systemic clearance, organ uptake, and tissue 
distribution, is necessary for in vivo efficacy. 
1.7.2 Pharmacokinetics Beyond the Cell 
Two of the main mechanisms for getting stabilized helices across membranes are charge and 
lipophilicity. Both are inspired by nature. Many natural compounds like cyclic peptides and 
cyclotides are highly stable and lipophilic. In contrast, viral approaches, such as the cationic 
TAT peptide from HIV, use charge to help penetrate membranes. As a cautionary note, cationic 
charge, particularly in combination with lipophilicity, is also found in a third class of molecules: 
anti-microbial peptides. These membrane-disrupting agents have the potential for high toxicity 
and may have narrow concentration windows for efficacy without toxicity. Likewise, viruses 
(and related gene-delivery payloads) benefit from amplification and integration within the cell, 
requiring relatively low doses, whereas peptide-scaffold delivery requires target-saturating 
amounts. Examples of both approaches are prevalent in the literature; how do these strategies, 
designed to allow access to the cytosol, impact the quantitative systems pharmacology of these 
agents? 
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The number of clinical examples of intracellular therapeutics outside Lipinski’s Ro5 
dwindles dramatically when approaching 1 kDa and above, and so too does the detailed data on 
tissue, organ, and systemic distribution. However, specific examples (both within and outside the 
class of stabilized peptides) can highlight some of the challenges and strategies to improve 
intracellular delivery in a clinically translatable manner. Although these agents do not currently 
have FDA approval, macromolecules against intracellular targets with significant published 
clinical results include imetelstat (a non-peptidic 4.6 kDa telomerase inhibitor) and the clinical 
test compound ALRN-69249 (the clinical variant of stapled peptide ATSP-7041). Typically 
molecules that have made it further in the clinical trial process have improved pharmacokinetic 
properties45. Looking at these molecules in conjunction with the cyclic peptides discussed 
previously, some trends are clear. Lipophilicity is much more prevalent than cationic charge for 
cytosolic access. This is also true for BCL-2 inhibitors (e.g. venetoclax and navitoclax), 
rapamycin, and a host of other ‘beyond Lipinski’ molecules (500-1500 Da)46,47. Even at the other 
extreme of the ‘non-Lipinski’ space, close to 5 kDa, molecules with high lipophilicity tend to 
prevail. Cyclotides, as natural products, are isolated based on their stability and long HPLC 
retention time (lipophilicity)48. By integrating a target-binding helix into a cyclotide’s backbone, 
Ji et al. were able to target MDM2 inside cells with a 5.3 kDa cyclotide. While the doses are high 
(40 mg/kg in 5% dextrose which can enhance permeability) likely due to slow transport, they 
have shown remarkable evidence of activity after oral administration against this intracellular 
target49. The use of lipophilicity does not preclude other mechanisms of cytosolic access from 
being integrated (and may be necessary for the intracellular delivery of larger cargos, such as 
DNA/RNA). However, it is worth highlighting the strengths of augmenting lipophilicity as an 
approach from a systems pharmacology perspective. 
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Focusing first on systemic delivery (plasma concentrations), lipophilicity can help slow 
down clearance in the blood to enable more efficient uptake in tissue. These peptide scaffolds are 
well below the roughly 60 kDa molecular weight filtration limit of the kidney, so hydrophilic 
scaffolds are rapidly excreted by the kidneys50. Lipophilic peptides (and small molecule drugs) 
typically bind albumin and other proteins to avoid renal filtration. Highly charged molecules can 
also stick to plasma proteins, but these are typically cleared rapidly by the liver. To highlight a 
clinical example, protamine, a cationic macromolecule that complexes with heparin in the blood, 
is cleared within minutes in humans (7.4 min half-life)51. While protamine may be an extreme, 
TAT and related peptides tend to exhibit increased clearance and liver/kidney uptake52,53. Serum 
proteins also decrease the cellular uptake of these agents, and care must be used when taking 
quantitative pharmacology measurements to discern what conditions were used. However, serum 
proteins tend to have a larger effect on cationic delivery (both peptides and larger cargoes such 
as PEI-mediated gene delivery) than lipophilic delivery11. Even if the serum binding can be 
avoided, this could potentially result in rapid kidney clearance as described above. High cationic 
charge can also disrupt membranes at higher concentrations, causing toxicity as previously 
mentioned. This could cause potential issues with parenteral routes of administration, such as 
subcutaneous injection or even intravenous delivery (e.g. infusion reactions) due to high local 
concentrations. Therefore, while exceptions may exist54, cationic ‘cell penetrating peptides’ 
generally have poor in vivo pharmacokinetics52. 
Lipophilic agents, though less susceptible to causing membrane toxicity, can suffer from 
issues of solubility. Here, stabilized peptides may be able to take advantage of the ‘chameleon’ 
like behavior of cyclic peptides, where intramolecular hydrogen bonds can form in membranes, 
but intermolecular bonds can form with water molecules in an aqueous environment55. Extreme 
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lipophilicity may also suffer from slow distribution into different organ systems due to high 
plasma protein binding (PPB). Although PPB is important to avoid rapid renal filtration, high 
PPB can slow the extravasation and diffusion rates of the compounds as seen with smaller 
molecules (e.g. ~1 kDa fluorescent PARP inhibitors)27. 
Tissue heterogeneity is another consideration for stabilized peptides, since the size of 
these agents may result in transport limitations over the tens to hundreds of microns length scale. 
Both small molecules and biologics can exhibit heterogeneity in tissue under certain conditions. 
Small molecules often exhibit heterogeneous distribution if they have rapid cell uptake and 
immobilization relative to clearance (e.g. Hoechst 33342)56 or fast metabolism relative to 
diffusion57. Antibodies exhibit heterogeneity when their binding rates exceed their diffusion into 
the tissue58. The large gradients in the drug concentration between the region just outside of the 
blood vessels and regions more distal to the vasculature arise through a competition between 
immobilization of the agent (receptor binding, cellular internalization, etc.) versus interstitial 
transport (typically diffusion dominates over convection in this size range). This ratio of an 
immobilization reaction to diffusion can be captured by a dimensionless number known as the 
Damköhler number. Because these agents lack an extracellular target, the relevant 
“immobilization” reaction rate is uptake into the cell. At first glance, it appears that there will be 
little heterogeneity in the tissue, since cellular uptake rates relative to diffusion are very slow for 
this class of agents (e.g. even with macromolecular imaging agents)59. However, caution must be 
exercised, since the strategies for increasing cell permeation (high lipophilicity and/or charge) 
can also dramatically slow the effective diffusion rate (while increasing the cellular 
uptake/immobilization rate). Continuous exposure from the blood can eventually overcome any 
transient gradients, but degradation of the probe could result in a scenario where the drug is 
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destroyed before it ever reaches distant cells, similar to antibodies60. Many tissues have relatively 
short distances between blood vessels, but tumors are particularly prone to this issue due to their 
long diffusion distances for efficient delivery61. While the stability imparted by cross-linked 
scaffolds for stabilized peptides and slow cellular uptake of these agents (relative to seconds for 
small molecules) help mitigate the risk of tissue heterogeneity, this is an important consideration 
when manipulating the physicochemical properties to optimize cellular uptake. 
1.7.3 Clinical Precedent 
In the absence of an FDA-approved drug, limited clinical data is available for intracellular 
targeted macromolecules. The two examples of drugs mentioned earlier that have been 
administered to patients – the clinical version of ATSP-7041 (a 1.4 kDa all-hydrocarbon stapled 
p53 mimetic) and imetelstat (a telomerase inhibitor which uses a fatty acid to increase 
lipophilicity) – illustrate the impacts of lipophilicity on the quantitative pharmacology and 
development of these agents. ATSP-7041 (Fig. 1.3)  was derived from a sequence (pDI) enriched 
by phage display62 and outfitted with an i,i+7 hydrocarbon staple51. This agent had high binding 
affinity to its target (Kd = 900 pM for MDM2), which is likely required due to low intracellular 
concentrations. The Verdine group had previously developed a similar p53-based stapled peptide 
inhibitor of MDM2 called SAH-p53-817; however, this peptide proved not potent enough for 
therapeutic application beyond very controlled in vitro assays63. It is therefore useful to look at 
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the differences between ATSP-7041 and SAH-p53-8 that may provide insight into properties 
needed for success. 
Although physicochemical properties beyond molecular weight are not reported for these 
peptides, important structural differences and their presumed effect on efficacy are outlined. 
Firstly, SAH-p53-8 and ATSP-7041 both contain three key hydrophobic residues (Phe19, Trp23, 
Leu26) required for binding MDM2/MDMX. However, several phage display studies have 
Figure 1.3 Constrained Peptide Types. (A) Linear peptides are those containing no backbone 
cyclization (neither between termini or residues). Enfuvirtide is a 36 amino acid linear peptide 
for HIV treatment. (B) Cyclosporine is a cyclic peptide with a completely cyclic backbone, 
therefore containing no terminus. Cyclosporine A is an immunosuppressant natural product 
cyclic peptide with several N-methylations in its backbone. (C) Cyclotides are cyclic peptides 
with intramolecular disulfide bonds, termed cysteine knots. Kalata B1 is a natural product 
cyclotide commonly used as a scaffold for its physical and chemical stability. (D) Stabilized 
peptides encompass peptides having residues chemically cross-linked by any one of various 
methods such as those outlined in Figure 1.1. ATSP-7041 is a clinical-lead stapled peptide by 
Aileron Therapeutics for inhibiting MDM2 in relevant cancer types. 
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revealed the importance of another key residue, Tyr22 (64). This replaced the residue Leu22 in 
SAH-p53-8, which was preserved from native p5363. Furthermore, SAH-p53-8 has additional 
residues 14-16, all of which are polar, and residues Gln17 and Arg24 are replaced with Leu and 
Ala, respectively, in ATSP-7041. Chang and colleagues explain that this enlarges the already 
existing “hydrophobic patch”, leaving only a total of 4 polar residues63. This essentially reduces 
the polar surface area of the peptide while also reducing its total size. These modifications 
resulted in a peptide with an aqueous solubility too low for peptide characterization. This 
sequence was therefore further modified to improve solubility without sacrificing amphiphilicity 
by replacing His21 with the charged Glu residue and adding two c-terminal Ala residues to 
extend the helix. The resulting sequence is ATSP-7041. Cell viability assays in 10% serum show 
a more than 50-fold increase in potency between SAH-p53-8 (IC50>30uM) and ATSP-7041 
(IC50=600nM). 
In vivo studies of ATSP-7041 showed that it is primarily excreted intact by the liver, 
resulting in 79% collected in the feces and < 3% in the urine. The reported half-life in humans is 
5.5 hrs63. Imetelstat also has a plasma clearance half-life of around 5 hrs in humans65 with 
primarily liver uptake but some kidney/bladder signal as measured by radiolabeling66. The 
relatively long half-lives compared to cationic agents provides some evidence that lipophilicity is 
a feasible mechanism to improve intracellular delivery for this class of drugs. Clinical plasma 
clearance is not the only shared trait between these intracellular targeted macromolecules. While 
the targets and structures are very different, they both contain modifications to achieve high 
stability, lipophilicity, and binding affinity. Imetelstat has a thio-phosphoramidite backbone to 
improve stability of the nucleic acid backbone67 (similar to the function of side-chain 
crosslinking for ATSP-7041), a conjugated 16 carbon fatty acid to increase lipophilicity and cell 
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penetration68 (comparable to the all-hydrocarbon staple for ATSP-7041), and high affinity and 
specificity for its target (45 pM67 for imetelstat and 900 pM for ATSP-7041) to bind at low 
intracellular concentrations. 
Significant work remains to determine if stabilized peptide scaffolds can generally be 
used to target intracellular proteins in the clinic. Major outstanding questions remain around the 
specific mechanisms of cellular uptake and other aspects of development. For example, how 
important is the distribution of lipophilic groups on the molecular surface versus net-
lipophilicity? What is the role of molecular shape? Many stabilized peptides are often seen in 
endosomes (which are inaccessible to the cytosol). Is this a necessary step for delivery of 
lipophilic stabilized peptides or simply a function of faster uptake into endosomes than 
permeability across these membranes? It is clear that multiple approaches for improving cellular 
permeability can work in cell culture, and lipophilic-mediated delivery may be a tougher 
approach. However, given the multiple benefits from a quantitative pharmacology standpoint for 
clinical translation, this may be the tougher road worth choosing. 
1.8 Discussion and Future Directions 
Few stabilized peptides thus far have been reported to have in vivo efficacy. However much can 
be learned from the combined knowledge in the field of small molecule drug development, 
biologics, and the few examples of agents that have entered the clinic as discussed here. It is 
clear that in the case of stabilized peptides, sequence optimization must take into account effects 
on binding affinity, solubility, membrane partitioning, clearance rate, and other pharmacokinetic 
processes. Hydrophobicity (lipophilicity) and the existence and location of polar residues seem 
to be important in the context of not only membrane permeability but also for protease 
degradation, plasma protein binding, and subsequent uptake and clearance rates as in the case of 
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ATSP-7041. Furthermore, even large peptides (> 1 kDa) are not precluded from having in vivo 
efficacy (and non-intravenous routes of administration), but the barriers are high. The examples 
discussed here point to the possibility that lipophilicity may be a useful property to balance 
cellular uptake with tissue distribution, organ biodistribution, and systemic clearance. Examples 
with related scaffolds indicate that it should stay within or close to Lipinski’s rules, even when 
other Ro5 guidelines are broken. 
Stabilized peptides stand at the interface between traditional small molecule drugs and 
larger biologics. Future directions should continue to take advantage of the unique contributions 
from each of these fields. Directed evolution methods developed for biologics can help in the 
selection of binders in the much larger ‘chemical space’ of these macromolecules. Similar to 
biologics, the plasma concentration of these agents is rarely the concentration at the site of 
action, and the concepts of multi-scale drug delivery can be employed to understand the various 
transport hurdles in vivo, going beyond the cellular delivery issue. Borrowing from the field of 
small molecules, leveraging data on lipophilicity, polar-surface area, charge, etc. to understand 
membrane permeability and partitioning will aid in our understanding of if and how these 
molecules access the cytosol and their targets. The hurdles for development are high, but the 
potential payoff – to be able to specifically hit targets beyond the reach of biologics and small 
molecules – would open up a vast array of new therapeutics. 
1.9 Boxes 
Box 1.1 Helicity 
 Alpha helices are coiled protein secondary structures held together by hydrogen bonding 
between amino acids that are 4 residues apart (i, i+4), which are commonly found in proteins and 
at interfaces 3. Helicity is a widely measured parameter for stabilized peptides, but the multiple 
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quantitative impacts of this property on binding have led to substantial debate. Increases in 
helicity result in a more ‘structured’ peptide, and a more rigid structure has long been known to 
enable selection of higher binding affinity molecules, whether this is from disulfide ‘constrained’ 
libraries in phage display69, fixing the termini by displaying peptides as ‘loops’ in a protein70, or 
disulfide bonds that are selected in CDR loops of antibodies71. However, this general finding is 
far from uniform and, at the molecular level, is complicated by the allowable ensemble of 
molecular conformations in the bound versus free states and the contribution of solvent effects72. 
The net impact on affinity can best be described by the thermodynamics of binding. The 
dissociation constant is related to the Gibbs free energy of binding, which in turn is comprised of 
the enthalpy of binding (a measure of the energy associated with charge interactions, van der 
Waals forces, and hydrogen bond contacts at the binding interface versus in free solution) and 
entropy (a measure of the loss in available conformations when it is bound to the target versus 
free in solution).  
 
 𝐾! = 𝑒"∆$/&' ∆𝐺 = ∆𝐻 − 𝑇∆𝑆 
 
 
By ‘locking’ a peptide in one conformation (or more accurately, increasing the probability that 
the peptide in free solution is found in this conformation), the ‘entropic penalty’ for binding can 
be decreased significantly. This is demonstrated in a study by Sia et al. as a uniform decrease in 
the –TΔS term with increased helicity; the difference in entropy between bound and free goes 
𝐾! = 𝑑𝑖𝑠𝑠𝑜𝑐𝑖𝑎𝑡𝑖𝑜𝑛	𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 ∆𝐺 = 𝐺𝑖𝑏𝑏𝑠	𝑓𝑟𝑒𝑒	𝑒𝑛𝑒𝑟𝑔𝑦	𝑜𝑓	𝑏𝑖𝑛𝑑𝑖𝑛𝑔 𝑅 = 𝑢𝑛𝑖𝑣𝑒𝑟𝑠𝑎𝑙	𝑔𝑎𝑠	𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝑇 = 𝑡𝑒𝑚𝑝𝑒𝑟𝑎𝑡𝑢𝑟𝑒 ∆𝐻 = 𝑒𝑛𝑡ℎ𝑎𝑙𝑝𝑦	𝑜𝑓	𝑏𝑖𝑛𝑑𝑖𝑛𝑔 ∆𝑆 = 𝑒𝑛𝑡𝑟𝑜𝑝𝑦	𝑜𝑓	𝑏𝑖𝑛𝑑𝑖𝑛𝑔 
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down, increasing affinity73. However, unless the molecular conformation of the helix is perfectly 
aligned with the conformation maximizing all molecular contacts, a more rigid structure can 
lower the enthalpy of binding (e.g. slightly mis-aligning a hydrogen bond), resulting in an 
eventual decrease in affinity with increasing rigidity.  
 From a thermodynamic perspective, a more rigid structure, pre-organized in the optimal 
bound conformation, will always be higher affinity due to the reduced entropic penalty upon 
binding ceteris paribus. However, in practice, all other aspects of binding are not equal. 
Improvements in affinity by rigidifying the ligand are often less than (and sometimes opposite 
of) those predicted by the entropy of binding due to the ‘enthalpy/entropy compensation’ 
phenomenon. This effect, where changes in the entropy and enthalpy of binding oppose each 
other when engineering an affinity ligand, have their origins in a variety of molecular 
mechanisms including perturbations in a system with multiple closely spaced energy levels, 
higher ‘enthalpic’ interactions restricting ‘entropic’ motion, and importantly, the large 
thermodynamic contribution of structured waters before and after binding72. This makes helicity 
an imperfect measurement for changes in binding affinity. In summary, while increased structure 
generally has the potential for higher affinity, this is not guaranteed for any individual 
interaction. 
Box 1.2 Routes of Administration 
 The three routes of administration that span common delivery approaches for both small 
molecule drugs and biologics are oral (PO), subcutaneous (SC), and intravenous (IV) delivery. 
Oral delivery is the most challenging for stabilized peptides due to their low permeability and 
poor stability from stomach acidity and digestive proteolysis. Some agents, like cyclosporine and 
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other cyclic peptides mentioned in the main text, can overcome these barriers. Others necessitate 
subcutaneous injection, or if the dose is too large, intravenous administration. 
 Oral delivery for larger peptides is typically limited to local delivery in the 
gastrointestinal tract74. The improved stability from side-chain crosslinking can enable some 
absorption, albeit low, following oral gavage as seen with a 36-residue double stapled enfuvirtide 
agent29,75. A more clinical advanced example is the phase III trial of a formulated version of 
semaglutide76. Here, a permeability enhancer in the formulation aids in protection and absorption 
for this 4.1 kDa molecular weight peptide. Even with these advances, absolute absorption is still 
relatively low, but semaglutide is an ideal candidate for this approach given its safety at high 
doses, high potency, and slow clearance (so a relatively large oral dose and small absorbed 
fraction are tolerable).  
 Subcutaneous injection is a common delivery route for peptides since it enables self-
administration and avoids degradation in the GI tract. The formulation and dose become 
important considerations given that a typical SC injection volume cannot exceed ~1 mL. Highly 
concentrated doses, depending on the physicochemical properties, could also cause local 
reactions. Recently, Zhang et al. demonstrated that peptide backbone stabilization can help 
increase the fraction of stabilized peptide absorbed after subcutaneous administration in mice24.  
 Intravenous administration is a common delivery method for biologics, such as 
monoclonal antibodies, that have to be given at high (e.g. multiple mg/kg) doses. For example, 
ALRN-6924 had a maximum tolerated dose of 3.1 mg/kg when given as a weekly intravenous 
infusion (3 doses every 4 weeks)9. One disadvantage for stabilized peptides is that they have 
faster clearance than antibodies, necessitating more frequent delivery. 
Box 1.3. Lipophilicity and LogP 
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 Lipophilicity is a key determinant of the pharmacokinetic behavior of small molecule 
drugs. A drug must be lipophilic enough to partition into membranes for efficient absorption and 
distribution and for long circulation time (high plasma protein binding and kidney reabsorption). 
However, it must not be too lipophilic that it suffers from high first-pass metabolism or 
insufficient aqueous solubility making it unsuitable for delivery. Lipophilicity is traditionally 
quantified as LogP, the octanol-water partitioning coefficient, a measure of the extent to which a 
molecule partitions into octanol (a surrogate for the lipid bilayer) versus the aqueous phase. 
Molecules with a logP > 0 favor lipids over aqueous dissolution. Lipinski’s rule of 5 states that a 
drug molecule should have a logP < 5 (generally between 0 and 5)25. This quantity can be 
calculated experimentally; however several computational programs exist allowing for high-
throughput logP measurements for drug libraries25. Though computational programs are often 
accurate for small molecules, it has previously been shown that calculated logP values for 
peptides often deviate greatly from the experimentally measured values and that the discrepancy 
increases as peptide size increases77,78. This is attributed to the failure of fragment-based 
approaches to adequately consider intramolecular interactions such as hydrogen bonding and the 
effects of cyclization30. One method to circumvent inaccuracies of computational peptide logP 
measurements is to measure HPLC retention times and compare it to the retention times of small 
molecules with known logPs using the same HPLC method. Bird and colleagues have recently 
used HPLC retention times to compare lipophilicities of several peptide variants to aid in 
optimization of stapled Bcl-2 targeting peptides and have correlated this parameter with 
improved cellular uptake44. Valko et al. have also recently developed HPLC retention time 
methods to assess the lipophilicities of various potential peptide therapeutics79. This approach 
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could be useful for giving more accurate predictions of lipid partitioning given the challenges of 
predicting intramolecular hydrogen bonding. 
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Chapter 2 Identifying Determinants of Cellular Uptake of Stabilized Peptides 
 
2.1 Abstract 
Intracellular delivery has long been considered a major shortcoming of peptide stabilized peptide 
therapeutics due to their large molecular weight. In this Chapter, we study two physicochemical 
properties that have the potential to enhance uptake—lipophilicity and positive charge. We take 
an incremental and quantitative approach to explicitly measuring the effects of these two 
properties by starting with a peptide sequence containing two negatively charged glutamic acid 
residues and incrementally replacing them with non-charged glutamine residues. We 
subsequently stabilize the resulting three sequences with three different cyanine dye-linker 
conjugates of varying lipophilicity as measured by apparent LogD. The resulting 9 stabilized 
peptide variants, each with a different combination of charge and lipophilicity, are incubated 
with cells, imaged, and analyzed for the amount of intracellular uptake. Results showed that less 
negative charge does increase uptake but lipophilicity had the most significant influence on 
uptake with a LogD~3-3.1 being the optimum range for maximum uptake in this series of 
peptides. 
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2.2 Introduction 
As previously mentioned, alpha helices (Fig 2.1a) are the most common secondary structures 
among proteins and are often involved in protein-
protein binding interactions. Identifying these 
interactions and designing peptides from helices 
engaged in the binding pocket as well as 
chemically stabilizing them to promote protease 
stability and increase binding affinity is the 
approach that several have taken. One widely 
studied protein/protein interaction that is a 
common drug target for cancer therapy is the 
p53/MDM2 interaction. P53 is a transcription 
factor that regulates cell growth and apoptosis as a response to DNA damage and cellular stress. 
Its activity is regulated by MDM2, an E3 ubiquitin ligase that marks p53 for degradation when its 
functions are not necessary. Loss of p53 activity is the most common deficiency in human cancer, 
whether due to mutation of the gene or due to overregulation of MDM216.  Several groups have 
developed p53-based MDM2 inhibiting peptides, as discussed in Chapter 1. The most common 
stapling technique among these peptides is the all-hydrocarbon staple, which is the technique that 
was used for ATSP-7041 that led to the clinical lead compound, ALRN 6924, developed by Chang 
et al. of Aileron Therapeutics9. This stapling method, however, reduces the design space with 
regard to the linker. Iterative optimization of the peptide is completely sequence dependent. Lau 
and colleagues, who also designed a p53-based peptide for therapeutic modulation of the p53-
MDM2 interaction, introduced a more simple method of creating different peptide variants. This 
Figure 2.1 Alpha Helix and Double-Click 
Stabilization. (A) Alpha helix with dotted 
lines representing hydrogen bonds. (B) 
Double-click stabilization via copper-
catalyzed azide-alkyne cycloaddition of 
linear peptide with bis-alkyne dye-linker. 
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method was first demonstrated by Torres and colleagues. Instead of cross reacting two 
complementary residues, they placed two azido-functionalized residues in i, i+7 locations and 
stapled the peptide with a di-alkyne linker by copper-catalyzed azide-alkyne cycloaddition (Fig 
2.1b) —a well characterized click chemistry reaction21,22. Lau employed this strategy and termed 
this technique “double-click” stabilization23. After optimizing non-natural amino acid placement, 
they altered stabilized peptide properties via iterative optimization of the linker instead of the 
sequence. That is, they altered linker properties such as charge and lipophilicity, and stapled their 
di-azido peptide with several of these linker variants. They performed many of the same 
experiments to assess the efficacy of the peptide including binding affinity for MDM2, proteolytic 
stability in mouse serum, and in vitro incubation with a cancer cell line to determine permeability 
and the effect on native p53 activity. They found that the peptide with the most positively charged 
linker proved to have the most therapeutic effect. This result is expected as positively charged 
molecules would have an affinity toward cell membranes, which are negatively charged. However, 
this therapeutic effect was observed at 100μM peptide concentrations6. Typical therapeutic drug 
doses yield plasma concentrations between .01-10μg/μL80. This is over one order of magnitude 
lower than the in vitro concentrations used by Lau. Therefore, drug toxicity to healthy cells is a 
concern for in vivo applications, especially for positively charged molecules such as theirs that 
readily interact with negatively charged membranes. Although this peptide has poor efficacy, we 
will use this peptide as a model for measuring cellular uptake. 
There is still much to be learned about the mechanisms by which peptides enter cells, 
however, Verdine and colleagues have determined that staple type and peptide charge are the two 
most important factors that determine cellular entry, with positively charged peptides more readily 
permeating cell membranes39. It is therefore not surprising that many of the “successful” MDM2 
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inhibiting peptides reported in literature with regard to  stabilized peptide permeability and efficacy 
have been with positively charged peptide sequences and linkers. In many cases, however, these 
successes have been reported with no definitive proof that the peptides are having on-target 
efficacy. Cationic molecules at high concentrations can disrupt cell membranes, thereby causing 
cellular stress and toxicity. Seeing as though p53 is a transcription factor activated by cellular 
stress signals, upregulation of p53 and induction of apoptosis may not be due to target binding of 
the peptide, but by membrane disruption. Furthermore, as mentioned previously, cellular activity 
of stabilized alpha helices is typically achieved at high concentrations (20-100μM)11. This further 
supports the likelihood that these cationic stabilized peptides are having membrane toxicity, which 
has now been shown to be true for many published stabilized peptides11,44. Given the risk of lytic 
activity with cationic peptides, in this chapter, we will maintain charges of no more than +1, and 
in future chapters where we test for efficacy of drug candidates, we will directly assess lytic 
activity.  
Various literature studying many types of peptide therapeutics (cyclic peptides, cyclotides, 
etc.) and ‘Beyond Rule of 5’ drug molecules has shown that lipophilicity (logD) and size are 
important determinants of membrane permeability, which is in line with the principles in 
Lipinski’s Rule of Five55. For ‘beyond Rule of Five’ molecules however, permeability decreases 
more rapidly with an increase in molecular weight. Furthermore, the larger the molecule, the 
smaller the window in which permeability and aqueous solubility co-exist81,82. As discussed in 
Chapter 1, FDA-approved drug molecules with added lipophilic moieties have emerged over the 
past few years, also signaling the importance of lipophilicity. We will therefore do a more 
controlled analysis of the effects of lipophilicity and charge on cellular uptake of stabilized 
peptides.  
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2.3 Results & Discussion 
In order to analyze the effects of charge and lipophilicity on cellular uptake of stabilized 
peptides, we chose a model peptide that would allow us to make incremental changes to its 
charge and LogD  with minimal residue modifications. The peptide, which we call Plp (p53-like 
peptide) (Fig 2.2), was developed by Lau et al. and was based upon residues 17-29 of native p53 
with  residue modifications made to increase helicity and binding affinity83. The sequence 
(ETFXDLWRLLXEN, where X=Azidohomoalanine) features three carboxylic acid residues and 
an arginine residue, yielding a net charge of -2. It also features two azidohomoalanine residues in 
i, i+7 positions for double-click stabilization. Substituting the two glutamic acid residues for 
their carboxamide  analogues (glutamine)  and stabilizing the peptide with linkers of varying 
lipophilicities will allow us to generate a series of peptides with different charges and 
lipophilicities. We opted to use fluorophore-conjugated linkers to track and quantify uptake. The 
three fluorophores chosen are cyanine dyes Cy5.5, Cy7.5 and Sulfo-Cy7 with charges of +1, +1, 
and -1, respectively (Fig 2.3). The resulting series of peptides is listed in Table 2.1. We 
Figure 2.2 Chemical Structure of Plp. Circled for emphasis: the two glutamic acid residues 
(blue circles) that are modified to alter charge as well as the two azidohomoalanine side 
chains (red circles) for double-click stabilization with various linkers.  
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stabilized three sequences, ranging in charge from -2 to 0, which yielded a total of 9 stabilized 
peptides.  
2.3.1 Lipophilicity (LogD) and Charge 
As discussed in Chapter 1, the octanol/water partitioning coefficient is widely used as a measure 
of lipophilicity, and these values are typically estimated computationally. These computational 
methods do not consider intramolecular interactions such as hydrogen bonding within peptides. 
Therefore, we opted to measure lipophilicities by HPLC retention times and estimated apparent 
LogD values (Table 2.1) based on standards with known LogD.  
 
 
 
Figure 2.3 Dye-Linkers. Cyanine dyes, developed for their excellent far-red to near-
infrared fluorescent properties, are typically hydrophobic from the conjugated ring 
structure (e.g. Cy5.5, left). The longer methine bridge of Cy7.5 increases the wavelength 
of fluorescence and the lipophilicity (center). Many cyanine dyes have sulfate groups 
added to improve hydrophilicity and solubility (e.g. SCy7, right). 
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Table 2.1 Stabilized Peptide Variants 
Peptide 
[charge] sequence Dye Charge 
Apparent 
LogD (pH 
7.4) 
—  cy5.5 +1 3.07 
—  cy7.5 +1 3.75 
—  scy7 -1 *** 
PLP[-2] ETFXDLWRLLXEN 
none -2 2.43 
cy5.5 -1 3.05 
cy7.5 -1 3.60 
scy7 -3 2.37 
PLP[-1] QTFXDLWRLLXEN 
none -1 2.55 
cy5.5 0 3.08 
cy7.5 0 3.63 
scy7 -2 2.38 
PLP[0] QTFXDLWRLLXQN 
none 0 2.66 
cy5.5 +1 3.09 
cy7.5 +1 3.66 
scy7 -1 2.39 
*** not measured 
 
Cy7.5 is the most lipophilic of the fluorophores with a logD of 3.75, followed by Cy5.5 
and finally Sulfo-Cy7 which is a hydrophilic sulfonated dye. As expected, the Cy7.5 conjugated 
variants were the most lipophilic while the Sulfo-Cy7 conjugated variants were the least 
lipophilic. It is also important to note that the non-stabilized peptides themselves are more 
lipophilic than Sulfo-Cy7 dye and that stabilization with Sulfo-Cy7 linkers made the peptides 
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less lipophilic. Given that Sulfo-Cy7 is a sulfonated, negatively charged dye, this is not 
surprising.  Conversely, Cy7.5 and Cy5.5 are positively charged non-sulfonated cyanine dyes 
and are therefore much more lipophilic than the non-stabilized peptides. Cy7.5 features an 
additional ring structure within the cyanine group, thereby increasing its lipophilicity over Cy5.5. 
We expect that the Cy7.5 and Cy5.5 conjugated peptides will more readily partition into the 
cell’s lipid membrane than the Sulfo-Cy7 variants. However, we will use the difference in 
lipophilicities between the two to determine whether there is an optimum lipophilicity. That is, if 
the peptide is approaching the limit of aqueous solubility, it may readily partition into the cell 
membrane but be slow to diffuse through. This may be the case for Cy5.5 as well, but if so, we 
expect this to be exacerbated with the Cy7.5 variants. For variants with the same linker but 
different sequences, the more negatively charged variants were less lipophilic than the more 
positively charged variants. This is due to the lack of solvent hydrogen bonding offered by the 
original glutamic acid residues upon substitution with glutamine. We will determine the effect 
that these incremental differences in charge has on cellular uptake, with the expectation that 
more positive charge will cause higher uptake. 
2.3.2 Imaging 
The first step to assessing uptake was imaging of cells incubated with peptide over various time 
points. To do this, we utilized HT1080 cells and incubated them with each stabilized peptide at 
100nM concentration for up to 24 hours. Though not quantitative with respect to uptake, images 
show that for all variants, the peptide is localized in punctate spots within the cells, signaling 
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uptake by endocytosis (Fig 2.4).  Though diffuse cytosolic signal is not visible, we may not be  
Figure 2.4 Cell Uptake Images. Dye-conjugated peptides were incubated with cells for up to 24 
hours and imaged. Images with the same fluorophore were window-leveled the same but 
window-leveling is different for different fluorophores to best visualize peptide localization. 
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able to qualitatively observe this if it was present, especially given the brightness of the punctate 
spots. Therefore, it is impossible to conclude from these results which peptide variants, if any, 
are able to diffuse through the membrane to reach the cytosol, whether directly from the bulk  
media, or through escaping endosomes. Another aspect that cannot be verified from this imaging 
alone is whether the peptides were partitioned into the membrane before being endocytosed or 
whether they were primarily pinocytosed. We expect that the more negatively charged and 
hydrophilic the peptides, the more likely it remains in the aqueous bulk and gets pinocytosed 
while the more lipophilic and positively charged variants partition into the membrane and enter 
the cell through endocytosis (as well pinocytosis). Quantitative uptake data will offer more 
insight into what uptake phenomena are occurring. 
The images demonstrate that charge does seem to have an effect on uptake rate. In the 
case of Cy5.5 and Cy7.5-conjugated peptides, the negatively charged variants show slower 
uptake over time compared to the neutral and positively charged variants. In the case of Sulfo-
Cy7 variants where all are negatively charged, it is more difficult to discern differences in uptake 
rate, however the most negatively charged variant (-3 charge) only begins to show uptake at 5 
hours while the others show uptake (qualitatively) starting at 3 hours. The actual amount of 
uptake over time will be quantified via bulk uptake measurements. 
2.3.3 Bulk Cell Uptake 
Uptake of stabilized peptides into HT1080 cells over 24 hours was quantified using bulk 
cell measurements in 96-well plates. The number of peptides per cell over time are plotted and 
the final 24 hour values are listed (Fig 2.5). As expected, across all dyes, the least negatively 
charged variants had the fastest uptake. That is, the stabilized plp[0] variants had the highest 
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uptake compared to plp[-1] and plp[-2] stabilized with the same dye-linker. Furthermore, Sulfo-
Cy7 variants had the lowest uptake with 105 peptides per cell at 24 hours. Given that these 
variants are the least lipophilic (and most negatively charged), pinocytosis is likely a major 
contributor to uptake of these variants which would lead to slower uptake overall. This is 
supported by the uptake curves which are much more linear than the Cy5.5 and Cy7.5 uptake 
Figure 2.5 Bulk Cell Uptake Measurements. Uptake curves (left) and maximum uptake 
amounts at 24 hours (right) are shown for all stabilized variants. Cy5.5 stabilized variants had 
maximum uptake amounts of ~108, followed by Cy7.5 stabilized variants which had uptake 
amounts of ~106 and lastly SCy7 variants which had uptake amounts of ~105. 
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curves, suggesting at least partial 0 order kinetics which is consistent with pinocytosis. In 
contrast, the Cy5.5-stabilized variants had the fastest uptake with 108 peptides per cell at 24 
hours. Uptake curves follow 1st order kinetics, suggesting non-specific, linear uptake (either 
directly across membranes or via endosomal uptake). As previously discussed, one of the goals 
of this project was to determine the optimal lipophilicity for efficient uptake and determine what 
is too lipophilic. The Cy7.5 variants with just 106 peptides per cell at 24 hours seem to be beyond 
the ideal lipophilicity range for uptake. Their uptake is more efficient than the more hydrophilic 
Sulfo-Cy7 variants, suggesting that the uptake mechanism is likely driven by more than 
pinocytosis. Given the high lipophilicity, the peptides are likely partitioning into the membrane 
and endocytosed; however, passive diffusion through the membrane after partitioning is slower 
with such a hydrophobic peptide. Increased serum binding may be another cause for slower 
internalization of the Cy7.5 variants compared to Cy5.5 variants. The Cy5.5 peptide variants are 
lipophilic enough to partition into the membrane, but may avoid extremely high protein binding 
of Cy7.5 peptides. Since the Cy5.5 and Cy7.5 uptake curves both seem to indicate first order 
kinetics, we conclude that the uptake rates are likely governed by both mechanisms and that the 
Cy5.5 variants are more efficiently able to be taken up by cells. 
2.4 Conclusions  
The goal of the work in this chapter was to elucidate the roles of charge and lipophilicity 
on cellular uptake. Literature has shown that both are important, but not in the controlled manner 
that we have presented here. Using the same peptide sequence with slight side chain 
modifications to incrementally change charge and various stabilizing linkers to alter LogDs, we 
showed that both impact uptake efficiency. Although we limited positively charged variants to a 
single +1 charge, those variants had significantly higher uptake (~50% more for Cy5.5plp[+1]) 
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than the neutral charged variant with the same linker. This result is promising for peptide design 
when trying to avoid membrane toxicity. Furthermore, even going from a negative charge to 
neutral charge provides improvements in uptake. The glutamic acid to glutamine substitution 
provided a minimalistic way to achieve the required charge modifications, however, there is a 
possibility that an increase in uptake yielded by an increase in charge could sacrifice other 
desirable properties, such as binding affinity, stability, and helicity. These effects will be 
explored in Chapter 2. 
Lipophilicity proved to be the most significant driver of uptake. Although the charge 
differences within dye groups caused changes in uptake, the difference in uptake between 
variants of different linkers was much more distinct. Cy5.5 variants had 24-hour uptake values of 
108—almost two orders greater than the Cy7.5 variants and 3 orders greater than the Sulfo-Cy7 
variants. Furthermore, although Cy7.5 variants are the most lipophilic with LogDs of 3.6-3.7, 
this proved to be too lipophilic for efficient uptake. We hypothesize that those variants may 
partition quickly into the membrane but are slow to diffuse through the membrane. Serum 
binding and aggregation may also be major factors precluding these variants from entering the 
cell more efficiently. We therefore conclude that the Cy5.5 variants are in the best lipophilicity 
range for this series of peptides (logD 3-3.1) and that Cy5.5plp[+1] has the most efficient uptake 
with a logD of 3.1 and a +1 charge. These results will help inform peptide design and 
characterization in Chapters 2 and 3. 
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2.5 Experimental Methods 
2.5.1 Peptide Conjugate Synthesis 
Peptides used in this chapter (plp[-2], plp[-1], and plp[0])were purchased in linear form from 
InnoPep, Inc. 
Dye-conjugated bis-alkyne linkers were synthesized as described by Zhang84. Briefly, to 
make the lipophilic and hydrophilic bis-alkyne linkers for conjugation to NHS ester 
fluorophores, N-boc-cadaverine or N-boc- 2,2’-(ethylenedioxy)diethylamine was dissolved in 
acetonitrile and mixed with DIPEA (3 equiv) and propargyl bromide (3 equiv). After stirring 
overnight, the reaction mixtures were subjected to flash chromatography (80:7:1 
chloroform:methanol:ammonium hydroxide). The desired linker fractions were collected, 
deprotected in 50% TFA in DCM, purified using reverse-phase HPLC, and characterized by 
electrospray ionization mass spectrometry (ESI-MS). All reagents were purchased from Sigma 
Aldrich. 
Linkers were conjugated to NHS ester fluorophores (Cy5.5, Cy7.5 and Sulfo-Cy7, 
purchased from Lumiprobe) in water buffered with 7.5% sodium bicarbonate. Reactions were 
stirred for 20 minutes before purification with reverse-phase HPLC in water and acetonitrile 
buffered with 0.1% TFA. Products were characterized via MALDI-TOF mass spectrometry. 
Peptides were double-click stabilized via copper catalyzed azide alkyne cycloaddition in 
1:1 tert-butanol:water with the bisalkyne dye-conjugated linkers (1 equiv). The peptides and 
linkers were mixed with copper (II) sulfate (10 equiv), tris-hydroxypropyltriazolylmethyl)amine 
(10 equiv) and sodium ascorbate (50 equiv) at room temperature overnight before HPLC 
purification in water and acetonitrile buffered with 0.1% TFA. Products were characterized via 
MALDI-TOF mass spectrometry. 
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2.5.2 HPLC Retention Time 
Peptides and standards were run on a reverse-phase HPLC column in mobile phase 
containing 50mM ammonium acetate at pH 7.4 in water and acetonitrile with a gradient of 10-95% 
over 50 minutes. Standards were chosen based on a previously published method for estimating 
logD from HPLC retention time 85. All standards used here have a logD(pH 7.4) greater than 0 as 
measured by ChemAxon MarvinSketch software and are acidic (with the exception of Cyclosporin 
A which is a neutral cyclic peptide) to best reflect the peptides analyzed, all of which are acidic 
and mostly water insoluble. A standard curve was generated and apparent logD’s were calculated 
from the standard curve equation (Appendix A). 
2.5.3 Imaging 
HT1080 fibrosarcoma cells cultured in DMEM supplemented with 10% fetal bovine serum and 
1% penicillin/streptomycin were plated in 8-well chamber slides at 1x105 cells/well and 
incubated at 37C overnight. The following day, peptides were dissolved in media to a final 
concentration of 100nM. Media was removed from the cell wells and replaced with media 
containing peptide. Cells were incubated with peptide for 0, 1, 3, 5, 8, and 24 hours before 
removing the peptide, washing with PBS, and imaging using an Olympus FV1200 confocal 
microscope with a 60x water immersion objective and the appropriate lasers for each 
fluorophore. Images in the same sample set were window-leveled with the same settings using 
ImageJ software. 
2.5.4 Bulk Cell Uptake 
HT1080 cells were plated in a 96 well plate at 1x105 cells/well and incubated at 37C overnight. 
In addition to the negative control and experimental wells, a set of wells was reserved for a final 
cell count at the end of the experiment to allow quantification of peptides per cell. The day after 
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plating, media was removed from the wells and replaced with media containing peptide at 
100nM. After peptide incubation, media was removed, cells were washed, cells reserved for the 
cell count were harvested and counted, and the experimental cell wells were treated with RIPA 
buffer with 0.5% BSA. Plates were covered with foil to protect from light and stored at 4C 
overnight. The following day, lysed cell samples were transferred to another plate and imaged 
using an OdysseyClx Imaging Systerm from LI-COR. Fluorescence intensity was converted to 
peptide conjugate concentration using standards curves generated with peptide dissolved in the 
lysis buffer (RIPA buffer with 0.5% BSA). Using the cell count, the volume of sample, and 
Avogadro’s number, peptide concentration was converted to the number of peptides per cell. 
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Chapter 3 Choosing Novel Early Stage Stabilized Peptide Drug Candidates 
 
3.1 Abstract 
In this Chapter, we analyze a series of novel stabilized peptides to determine which peptides 
have the best therapeutic potential based on binding affinity and in vitro efficacy and toxicity. 
The peptides presented here were discovered via Stabilized Peptide Engineering with E. Coli 
Display (SPEED)—a high throughput bacterial surface display and stabilization technique to 
screen peptide libraries against targets of interest. Select high affinity MDM2 binders identified 
through this method were synthesized via solid phase peptide synthesis and tested for in solution 
binding affinity, helicity, cell-killing efficacy, and off-target membrane toxicity. We found that 
although helicity increased upon stabilization, helicity itself was not an indicator of high binding 
affinity or efficacy when comparing between peptides. The most promising of the peptides in the 
series is pepC—a disulfide containing peptide with a Kd of 1.7nM stabilized. When compared to 
a highly potent all-hydrocarbon stapled peptide with a 0.91nM Kd, ATSP-7041, stabilized pepC 
has similar in vitro efficacy in two cell lines as well as negligible membrane toxicity. 
Surprisingly, another novel peptide discovered via SPEED with a kd of 5.1nM stabilized, pepG, 
showed no efficacy despite its high binding affinity. We conclude that on-target efficacy in cells 
is not directly proportional to binding affinity for these agents. 
3.2 Introduction 
There are several methods that have been developed to discover novel peptides to block PPIs. 
Once a PPI has been identified, one must design a peptide sequence with more favorable binding 
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to the protein of interest than the native binding partner. The most high-throughput of these 
peptide discovery methods are display techniques (e.g. phage display, mRNA display, etc.)86,87 
that exploit cellular machinery to create vast libraries of unique peptides that can be screened 
against targets, sorted, and identified via genetic sequencing. One such technique, developed by 
my colleague, is Stabilized Peptide Engineering with E. Coli Display (SPEED)88. This is a 
bacterial surface display technique yielding libraries of up to 109 peptides that are double-click 
stabilized directly on the bacterial surface prior to screening with the target protein. Using this 
method, we identified a series of high affinity stabilized peptide binders to MDM2. Although 
peptides may show good target binding on the bacterial surface, this does not necessarily 
translate to efficient in-solution binding as well as other properties. The objective of this chapter 
is to identify possible drug candidates for further study of physicochemical properties based on 
in-solution binding affinity and in vitro efficacy.  
  The starting peptide used as a template in Chapter 2, plp[-2], was used as a point of 
comparison in the bacterial surface screening of MDM2-binding peptides with SPEED. As 
discussed in Chapter 2, plp[-2] has shown in vitro efficacy at only high concentrations. In this 
chapter, we probe the binding affinity and efficacy of this peptide and the other charged variants, 
plp[-1] and plp[0], alongside the novel sequences discovered with SPEED. These results provide 
insight into ultimately identifying the most important parameters that determine efficacy in 
addition to the determinants of cellular penetration which were explored in Chapter 2. 
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3.3 Results and Discussion 
3.3.1 Binding affinity 
The peptides in this study were discovered via SPEED with propargyl ether as the chosen linker. 
Since MDM2-inhibiting peptides are lipophilic given the hydrophobic binding pocket, this linker 
provides some added aqueous stability. For the in-solution studies (in contrast to the initial cell 
surface characterization), we opted to use this same linker as the results of the bacterial surface 
selection process. Recent work has demonstrated that the peptide properties are linker-dependent 
and target binding affinities could be drastically altered with the use of a different linker. The 
binding affinities of the propargyl ether stabilized peptides in solution, measured by biolayer 
interferometry, are listed in Table 3.1. Plp[-2] has a binding affinity of 15nM, a 7.5-fold 
improvement over its non-stabilized form. In Chapter 2, we saw that incrementally increasing the 
charge of plp[-2] yielded improvements in cellular penetration; however, those results did not 
provide information on how those changes would affect target engagement. Here, we see that 
those changes negatively impacted the binding affinity of the peptide, with plp[-1] and plp[0] 
having 17nM and 74nM Kd’s, respectively. This result exposes a potential issue when 
engineering peptides without the help of high-throughput directed evolution techniques. Even 
small changes to one sequence in hopes of creating more favorable biophysical characteristics 
can alter the binding interaction with the target. We therefore shift our focus to the novel 
sequences discovered.  
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Table 3.1 Peptide Molecular Weights and Binding Affinities 
Name Sequence Molecular Weight Binding Affinity (nM) 
 X= 
Azidohomoalanine Stabilized 
Non-
stabilized Stabilized 
Non-
stabilized △ 
plp-2 ETFXDLWRLLXEN 1823.0 1728.9 15 ± 5.3 113 ± 16 7.5 
plp-1 QTFXDLWRLLXEN 1822.0 1727.9 17 ± 3.4 157 ± 29 9.2 
plp0 QTFXDLWRLLXQN 1821.0 1726.9 74 ± 28 454 ± 106 6.1 
pepG GGTFXGYWADLXAF 1690.8 1596.7 5.1 ± 4.7 21 ± 3.7 4.1 
pepV VLSFXDYWNLLXGS 1800.9 1706.8 14 ± 4.3 131 ± 40 9.4 
pepC VCDFXCYWNDLXGY 1881.0 1787.7 1.7 ± 0.16 6.8 ± 2.8 4 
plp-2 
F19A ETAXDLWRLLXEN 
1746.9 1652.8 604 ± 177 >10,000 - 
pepC 
F19A VCDAXCYWNDLXGY 1805.7 1712.8 
2781 ± 
1202 
3888 ± 
2007 1.4 
 
The novel peptides displayed here were the variants with the lowest Kd’s. PepG, the 
lowest molecular weight peptide in the series, has a 5.1nM binding affinity—a 3-fold 
improvement over plp[-2] and a modest 4-fold improvement over the non-stabilized pepG. PepV 
has a binding affinity of 14nM, similar to plp[-2], but with a 9.4-fold improvement over its non-
stabilized form—the largest fold improvement in binding affinity from non-stabilized to 
stabilized out of all peptides in this series. PepC, which features  i, i+4 cysteine residues that 
form a disulfide (Fig. 3.1),  has the best binding affinity with a Kd of 1.7nM. Even in non-
stabilized form, its 6.8nM Kd is lower than the Kd of all other stabilized variants except pepG. 
The final two peptides in Table 3.1 are the non-binding F19A mutants of plp[-2] and pep[C], 
 47 
both of which serve as negative controls for the binding affinity assay. In the next section, we 
examined the helicity of each variant in the context of the binding affinities. 
3.3.2 Helicity 
As discussed in Chapter 1, increased helicity, achieved by chemically stabilizing peptides, often 
promotes increased binding affinity as well as proteolytic stability. The affinity measurements 
showed that for all peptides, stabilization increased binding affinity. Here, we measure the 
percent helicity of each peptide in non-stabilized and stabilized form to determine 1) whether 
stabilization did in fact increase the helicity and 2) if more helical peptides are generally tighter 
Figure 3.1 Chemical Structure of PepC 
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binders. Helicities were calculated from molar ellipticities measured by circular dichroism 
(Figure 3.2).  Table 3.2 shows the percent helicities for each peptide. Firstly, the data shows that 
all peptides are more helical in stabilized form than in non-stabilized form, however the fold-
change in helicity varies widely. Plp[-2] is by far the most helical peptide with 53% helicity in 
stabilized form, a 1.8-fold increase over non-stabilized. Interestingly, plp[-2] has the lowest 
binding affinity despite having the highest helicity, suggesting that binding affinity is more  
 
Table 3.2 Peptide Helicities 
Name Helicity (%) 
 Stabilized Non-stabilized △ 
plp-2 53 30 1.8 
plp-1 40 29 1.4 
plp0 41 37 1.1 
pepG 18 17 1.1 
pepV NM NM - 
pepC 28 4 7 
plp-2 F19A 50 14 3.7 
pepC F19A 37 31 1.2 
 
 sequence dependent than helicity dependent, as others have also shown83,89. PepG has the lowest 
percent helicity despite having the second-best binding affinity. Furthermore, stabilization had a 
minimal effect on helicity with a modest increase of 1% upon stabilization. The lack of helicity 
in this peptide is not surprising as it contains 3 glycine residues which are considered to be 
“helix-breakers”90 similar to the effects of proline, n-methylated amino acids and D-amino acids. 
Though still a strong binder despite low percent helicity, pepG may be susceptible to more rapid 
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degradation than the more helical peptides in the series, which could ultimately hinder efficacy. 
PepC experienced the largest increase in helicity upon stabilization with a 7-fold increase from 
just 4% to 28% helicity. The lack of helicity is likely due in part to the disulfide bond, as the 
reduced form of the peptide is more helical than the oxidized, as we have previously reported88. 
Again, given that the binding affinity of the non-stabilized pepC is stronger than most stabilized 
variants in this series, the sequence dependence is more significant than the percent helicity. 
Lastly, pepV, the variant with the biggest improvement in binding affinity upon stabilization, 
does not have a reported percent helicity due to the peptide being too hydrophobic to perform the 
measurement. Since helicity measurements were taken in 1:1 water: acetonitrile, the lack of 
solubility in this partly organic solvent could be a significant liability in the aqueous extracellular 
and intracellular environments.  
3.3.3 In vitro efficacy 
Based on the binding affinities, we chose a subset of peptides in this series to assess efficacy—
pepC, pepG, plp[-2] and the non-binding control, pepC F19A. PepC and pepG have the best 
binding affinities and therefore show promise as possible early stage lead compounds. Though 
previously reported data for plp[-2] shows low efficacy at high concentrations (Chapter 2), we 
measured the efficacy with a propargyl ether linker, which has not been reported. We did not 
include the other charged variants, plp[-1] and plp[0] due to their low binding affinities 
compared to plp[-2]. We also did not include pepV due to its low aqueous solubility, making it 
difficult to handle in in vitro assays. As a point of comparison for efficacy, we included the all-
hydrocarbon stapled MDM2-inhibiting peptide, ATSP-7041, that has a reported binding affinity 
of 0.91nM and is the precursor to a clinical lead compound currently undergoing clinical 
trials9,63. 
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 Cell viability in the presence of stabilized peptides (denoted with s-) after a 5-day 
incubation was measured in two p53-sensitive cell lines, SJSA-1 and LnCAP (Figure 3.3), and 
two p53-insensitive cell lines, Saos2 and DU145 (negative controls) (Figure 3.4). Results show 
that ATSP-7041 is the most potent in both SJSA-1 and LnCAP cell lines with IC50’s of 579nM 
and 168nM, respectively. PepC follows closely in efficacy with 665nM and 182nM IC50’s, 
respectively. Surprisingly, pepG shows little to no efficacy in these cell lines, despite having 
only 3-fold lower binding affinity than pepC. Not surprisingly, however, plp[-2] also shows little 
to no efficacy in these p53-sensitive cell lines.  
 Cell viability in the p53-insenstive cell lines Saos2 and DU145 was measured to assess 
off-target toxicity, as these cell lines do not express a functional p53 gene and are therefore 
insensitive to MDM2 inhibition. In Saos2, all peptides showed little toxicity in the measured 
concentration range. In DU145 however, pepG showed some toxicity (IC50=1629nM), 
suggesting some off-target toxicity. In order to further study the off-target effects of these 
peptides, we directly assessed membrane toxicity, a major concern for peptides with intracellular 
targets. 
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Figure 3.3 Cell Viability in p53-sensitive Cell Lines 
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3.3.4 Membrane Toxicity 
 Lipophilic and amphiphilic peptides, particularly those that are positively charged, can induce 
non-specific cell death by directly interacting with and permeabilizing cell membranes 11. To 
detect if any of these peptides were permeabilizing cells, we used lactate dehydrogenase leakage    
Figure 3.4 Cell Viability in p53-null Cell Lines 
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(LDH) as a measure of membrane toxicity. Using the same p53-null cell lines, Saos2 and 
DU145, cells and peptide were incubated with and without serum for 24 hours (to minimize the 
Figure 3.5 LDH Leakage 
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effects of cell doubling on assay sensitivity). Results, shown in Figure 3.5, show that only ATSP-
7041 and pepC show minimal LDH leakage in Saos2 which is exacerbated by the removal of 
serum. Furthermore, only ATSP-7041 shows minimal LDH leakage in DU145. Given that the 
LDH leakage assay was done over 24 hours while the cell viability assay was done over the 
course of 5 days, there is a possibility that damage might occur over 5 days that is not captured in 
just 24 hours. However, given the lack of any LDH leakage by pepG and the slight LDH leakage 
of  ATSP-7041 which did not show considerable cell-killing in the 5-day viability assay in the 
insensitive cell lines, it is likely that the mechanism of pepG’s cell-killing in DU145 is caused by 
something other than membrane damage. Furthermore, these data, as well as the cell killing 
results above, support the notion that the efficacious peptides are largely cell penetrant in a 
manner that leaves cell membranes intact. 
 
3.4 Conclusions 
In this chapter we explored a series of peptides engineered through a bacterial surface display 
and stabilization method developed in our lab. We took the sequences that yielded the best 
binding affinities on the bacterial surface, synthesized and stabilized the peptides in solution, and 
measured their in-solution binding affinities, helicities, and in vitro efficacy. Binding affinity 
results showed that incrementally increasing the charge of plp[-2] by substituting the glutamic 
acid residues with glutamine caused a decrease in binding affinity, especially for plp[0] which 
had a drastic 5-fold increase in Kd over plp[-2]. This supports the need for a high-throughput 
screening technique like SPEED so that various high affinity peptides can be engineered and 
later tested for favorable in vitro properties without needing to make potentially detrimental 
alterations to an existing sequence. Furthermore, binding affinity results showed that there are 
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two novel high affinity peptides, pepC and pepG, with 9 and 3-fold lower Kd’s than plp[-2]. Both 
peptides proved to be far less helical than plp[-2], showing that binding affinity is more sequence 
dependent than helicity dependent when comparing across various peptides. Although we might 
have expected both pepC and pepG to have better in vitro efficacy than plp[-2], data showed that 
only pepC has efficacy, signaling that binding affinity may be only a partial factor in the efficacy 
(or lack thereof) of pepG and peptides in general. Finally, pepC is remarkably close in potency to 
ATSP-7041, making it a promising lead peptide for further therapeutic development. 
The goal of this chapter’s work was to identify early stage lead peptides for further study 
of physicochemical properties that promote efficacy. We have identified one peptide, pepC, with 
high in vitro potency, comparable to the published ATSP-7041. Many outstanding questions 
remain, including why pepC and ATSP-7041 have efficacy while the other peptides (plp[-2] and 
pepG) do not. ATSP-7041 and pepC have the best binding affinities, but peptides with only 
slightly higher Kd values, such as pepG, have no detectable on-target cell killing. Clearly, other 
factors impact the quantitative efficacy of these agents, but the magnitude of these factors 
remains unknown. The rate of cellular penetration, which is determined by a number of factors 
including lipophilicity, amphiphilicity, and charge, is widely acknowledged to be important. One 
must also consider proteolytic stability which affects how much peptide is available to engage 
with the target once inside the cell. In Chapter 4, we quantify the physicochemical properties we 
believe are the biggest determinants of efficacy in order to answer the question of why some 
peptides in our series showed efficacy while others did not. 
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3.5 Experimental Methods 
3.5.1 Peptide Synthesis 
Peptides were synthesized via solid phase peptide synthesis in dimethylformamide (DMF) on a 
CEM Liberty Blue Microwave Peptide Synthesizer using Fmoc amino acids, HBTU activator, 
diisopropylethylamine (DIPEA), hydroxybenzotriazole (HOBt) and Rink amide resin. Post-
synthesis, peptides were rinsed with dichloromethane (DCM) and cleaved with a cocktail of 95% 
(v/v) trifluoroacetic acid (TFA), 5% (v/v) H2O, 5% (w/v) phenol, and 2% (v/v) triisopropylsilane 
(TIPS) under nitrogen bubbling for 2-4 hours. After cleavage, TFA was evaporated under 
nitrogen and the remaining peptide solution was ether precipitated in tert-butyl methyl ether and 
stored at -20C overnight before lyophilizing to powder. Fmoc amino acids, HBTU and resin 
were purchased from ChemPep, Inc. All other reagents were purchased from Sigma Aldrich.  
 Peptides were stabilized with propargyl ether via copper catalyzed azide-alkyne 
cycloaddition as described in section 2.4.1. Peptides were characterized with electrospray 
ionization mass spectrometry and HPLC (Table 3.3). 
ATSP-7041 was provided by the University of Michigan Peptide Synthesis Core. 
3.5.2 Biolayer Interferometry 
Binding affinity of peptides to MDM2 truncate (residues 10-118) was performed with biolayer 
interferometry (BLI) using an Octet Red96 system (ForteBio). MDM2 truncate was biotinylated 
with NHS-PEG4-Biotin (Thermo Fisher) and diluted to 500nM in assay buffer (0.3% (w/v) BSA 
in  phosphate buffered saline (PBS)) before being immobilized onto Super Streptavidin 
Biosensors. Peptides were diluted in assay buffer at 10 concentrations—each plated in a 96-well 
plate for binding affinity measurements according to the manufacturer’s protocol. Resulting 
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binding kinetics curves were fit in GraphPad Prism. Binding curves are documented in 
Navaratna 202088. 
Table 3.3 Peptide Characterization 
Name Sequence Stabilized % Purity Non-stabilized % Purity 
  Predicted 
Mass 
Observed 
Mass 
HPLC 
214nm 
Predicted 
Mass 
Observed 
Mass 
HPLC 
214nm 
plp-2 ETFXDLWRLLXEN 1823.0 1823.0 97.7% 1728.9 1728.9 >98% 
plp-1 QTFXDLWRLLXEN 1822.0 1822.0 95.8% 1727.9 1727.9 95.4% 
plp0 QTFXDLWRLLXQN 1821.0 1821.0 95.1% 1726.9 1726.9 97.7% 
pepG GGTFXGYWADLXAF 1690.3 1690.8 96.2% 1596.7 1596.7 >98% 
pepV VLSFXDYWNLLXGS 1800.9 1800.9 >98% 1705.8 1705.8 >98% 
pepC VCDFXCYWNDLXGY 1881.7 1881.0 >98% 1787.7 1787.7 97.5% 
plp-2 
F19A ETAXDLWRLLXEN 1746.9 1746.9 >95% 1652.8 1652.8 >95% 
pepC 
F19A VCDAXCYWNDLXGY 1805.7 1805.6 >98% 1712.8 1712.7 >98% 
 
3.5.3 Circular Dichroism 
Percent helicity was measured by circular dichroism using a JASCO J-815 spectropolarimeter. 
Peptides were diluted in assay buffer (1:1 water:acetonitrile) to 10uM and transferred to a 1mm 
path length quartz cuvette. All measurements were taken in three accumulations from 25nm to 
190nm and percent helicities were computed based on molar ellipticities at 222nm. 
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3.5.4 Cell Viability Assay 
Cell viabilities in the presence of stabilized and non-stabilized peptides were assessed in four 
human cancer cell lines. The p53-sensitive cells lines used here are SJSA-1 (osteosarcoma) and 
LnCAP (prostate adenocarcinoma) with Saos2 (osteosarcoma) and DU145 (prostate 
adenocarcinoma) serving as p53-null and mutant p53-expressing negative control cell lines, 
respectively. Each cell line was passaged with 10% Fetal Bovine Serum (FBS), 1% 
penicillin/streptomycin, and respective culture media: SJSA-1, LnCAP, and DU145 in RPMI 
1640; Saos2 in DMEM. Upon confluency, cells were plated in triplicate in 96-well plates at the 
following cell densities: DU145 and SJSA-1 at 500 cells/well, Saos2 at 2,000 cells/well, and 
LnCAP at 4,000 cells/well, and incubated at 37°C for 24 hours. Each cell line was treated with 
each of the four peptides: pepG, pepC, plp[-2] and ATSP-7041. PepG, pepC and plp[-2] were 
tested in non-stabilized and propargyl ether stabilized forms while ATSP-7041 was tested as is 
and in its hydrocarbon stapled form. Peptides were added to cells in concentrations ranging from 
0 (vehicle only control) to 10µM in media with 10% FBS and plates were incubated for five days 
at 37ºC. Assays were ended with PrestoBlue cell viability reagent according to manufacturer’s 
protocol (ThermoFisher). Excitation and emission were measured at 560 nm and 590 nm, 
respectively, using a Biotek plate reader. Data from peptide treated wells were normalized to the 
vehicle-treated peptide-free control and corrected for background fluorescence. The resulting 
data were curve-fit and IC50s were calculated with GraphPad Prism v.8 software using a 
log(inhibitor) vs. response variable slope model. 
3.5.5 Lactose Dehydrogenase Leakage Assay 
Plasma membrane damage, as indicated by lactate dehydrogenase (LDH) leakage, in the presence 
of stabilized peptides was assessed in two p53-null human cancer cell lines, Saos2 (osteosarcoma) 
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and DU145 (prostate adenocarcinoma). Each cell line was passaged with 10% Fetal Bovine Serum 
(FBS), 1% penicillin/streptomycin, and respective culture media: DU145 in RPMI 1640 and Saos2 
in DMEM. Upon confluency, cells were plated in triplicate in 96-well plates at the following cell 
densities: DU145 at 5,000 cells/well and Saos2 at 20,000 cells/well, and incubated at 37°C for 24 
hours. Media was then aspirated from all wells and cells were washed with their respective assay 
media (with or without serum) before being treated. Each experiment included side-by-side sets of 
triplicate wells where one set was tested with serum and the other without. Within each of these 
sets was one experimental condition-- cells treated with peptide at 10uM in media--and two 
controls. Vehicle-only treated cells served as a negative LDH control and vehicle-only treated cells 
with lysis buffer (0.8% Triton X-100) added at the end of the experiment served as a positive LDH 
control. Each set also contained cell-free wells mimicking the experimental and control wells to 
normalize for background fluorescence in each condition. Plates were incubated at 37°C for 24 
hours and lysis buffer was added to positive control wells 45 minutes prior to the assay endpoint. 
LDH leakage was quantified with the CyQuant LDH Cytotoxicity Assay Kit (Invitrogen C20301) 
per manufacturer’s protocol. Fluorescence measurements were taken with a Biotek plate reader. 
Percent LDH leakage was calculated with the following equation:  
%	𝐿𝐷𝐻	𝐿𝑒𝑎𝑘𝑎𝑔𝑒= (𝑝𝑒𝑝𝑡𝑖𝑑𝑒 − 𝑝𝑒𝑝𝑡𝑖𝑑𝑒	𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) − (𝑣𝑒ℎ𝑖𝑐𝑙𝑒 − 𝑣𝑒ℎ𝑖𝑐𝑙𝑒	𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)(𝑙𝑦𝑠𝑒𝑑 − 𝑙𝑦𝑠𝑒𝑑	𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) − (𝑣𝑒ℎ𝑖𝑐𝑙𝑒 − 𝑣𝑒ℎ𝑖𝑐𝑙𝑒	𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) 	𝑥	100 
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Chapter 4 Profiling Physicochemical Properties of Peptide Candidates and Analyzing 
Correlation to Efficacy 
 
4.1 Publication Information 
L. Atangcho, T. Navaratna, M. Mahajan, M. Case, K. Deprey, H. Levy, R. Gopinath, G. 
Gueorgiev, J. Kritzer, G. Thurber. Protease stability correlates with efficacy for high-affinity, 
cell-penetrant MDM2-binding stapled peptides. In prep. 
4.2 Abstract 
Nearly two-thirds of all disease-associated proteins are ‘undruggable’ by modern therapeutics, 
meaning they are inside cells, out of the reach of biologics, but lack small molecule binding 
pockets. Stabilized peptides have the potential to hit these targets. However, the design criteria for 
developing agents that can reach and disrupt their target are poorly understood. This work focuses 
on the physicochemical properties of three newly-developed high affinity double-click stabilized 
MDM2/p53 inhibiting peptides that have favorable in vitro characteristics including protease 
stability, cytosolic access, and target-specific cell killing. These properties are distinct from ATSP-
7041, the only p53-based peptide that has led to a clinical lead compound. We highlight a 
promising peptide variant with an added disulfide-bond backbone modification that demonstrates 
sub-micromolar cell-killing in the presence of serum, comparable to the published in vitro potency 
of ATSP-7041. Overall, these peptides help better define the landscape needed for effective 
intracellular biologics. 
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4.3 Introduction 
Drug development for intracellular targets is dominated by small molecules that can readily cross 
cell membranes and can often be administered orally. The screening and discovery of lead 
compounds was significantly advanced when the capabilities of high-throughput screening were 
paired with heuristics, such as Lipinski’s Rule of Five25, that identified compounds with 
appropriate ‘drug-like’ properties like solubility and membrane permeability. These advances led 
to a dramatic reduction in clinical attrition rates due to pharmacokinetics and bioavailability91, with 
contemporary drugs able to rapidly enter cells and bind their targets in minutes26. Nonetheless, 
small molecules are unable to target the majority of disease-associated protein-protein interactions 
(PPIs)2,3 because PPIs involve large binding interfaces often 2000 to 4000 Å2 or more of buried 
surface area92. Furthermore, these targets reside inside the cell, out of the reach of traditional 
biologics (i.e. antibodies) with extracellular targets. This spurred new research into novel classes 
of agents that had the potential to reach these ‘undruggable’ targets. 
To target intracellular PPI’s, a significant effort has focused on molecules at the interface 
of traditional small molecule drugs and macromolecular therapeutics. These so-called ‘Beyond 
Rule of Five’ molecules, often cited as 500-5,000 Da in size, in theory possess the ability to cross 
membranes but bind larger, more hydrophilic interfaces such as PPI’s. Many of these compounds 
are inspired by natural products, such as cyclosporin and cyclotides/knottin peptides49,93–95 and 
several have demonstrated clinical efficacy and FDA approval65,77,96,97. However, the diverse 
pharmacokinetics, cytosolic delivery mechanisms, and overall design criteria for this broad class 
of agents is not well-defined, and continued advances are needed98. 
Stabilized peptide therapeutics are one class of agents in the Beyond Rule of Five space 
being explored as a solution to this shortcoming. Given that many PPIs have alpha-helical binding 
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interfaces3, helical peptides in particular are being developed to inhibit these interactions with high 
specificity99. Furthermore, structural stabilization via covalent chemical modification generally 
yields enhanced target binding affinity as well as increased proteolytic stability and cell 
penetration20,88,100–102. All-hydrocarbon linkers (stapled peptide therapeutics) were pioneered by 
Walensky and colleagues (Verdine and Korsmeyer groups) against a variety of targets including 
BCL-2 and MDM2 domains5,14,17,41,44,103. Lau and colleagues (Spring group) developed peptides 
for the same target but employed the use of the double-click stabilization technique for an added 
degree of freedom in chemical modification6,21,83. In 2013, Chang and colleagues published a 
stapled p53/MDM2 inhibiting peptide, ATSP-7041, that went on to be the basis for the first and 
only stabilized peptide therapeutic in clinical trials thus far, ALRN-69249,96,104. The demonstrated 
clinical effects of this peptide are a big step for the field; however there is still much progress to 
be made for an overall mechanistic understanding of the physicochemical properties required for 
these agents to be clinically effective drugs. Recent literature in stapled peptide design has shown 
advancements in sequence optimization strategies for cell penetration and protease stability in 
addition to high affinity 41,44,89. These kinetic processes are the major rates controlling cell efficacy: 
cytosolic delivery versus clearance determine intracellular concentration while affinity establishes 
the target fraction bound (Fig 4.1). However, the quantitative trade-offs between properties are  
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incompletely understood, making it challenging to define criteria for successful agent design. Here, 
we quantify the cytosolic penetration rate, membrane interaction, target binding, and protease 
stability of a series of high affinity MDM-2 binding agents to identify the combination of 
properties needed for cell efficacy.  
 
We previously developed a series of MDM2-binding stapled peptides with high affinity 
via Stabilized Peptide Evolution by E. Coli Display (SPEED)88. (Here, ‘stapled peptide’ refers 
broadly to side-chain cross-linked peptides, not exclusively hydrocarbon metathesis chemistry.) 
With propargyl ether as the stabilizing linker, the resulting clones were screened against MDM2. 
Those with the highest binding affinity were sequenced and synthesized via solid phase peptide 
synthesis (SPPS), stapled with the propargyl ether linker, and re-tested in solution. In this work, 
we measured the quantitative cellular pharmacology of these agents to access and inhibit MDM2. 
Figure 4.1 Overview of Relevant Rates 
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Continuing on from Chapter 3, here we begin with measuring cellular penetration followed by 
biophysical membrane interactions and ending with proteolytic stability.  
 
4.4 Results 
4.4.1 Cytosolic Penetration  
The chloroalkane penetration assay (CAPA), developed by Peraro and colleagues, is a HaloTag-
based pulse-chase assay that provides a quantitative measure of cytosolic penetration105. Briefly, 
chloroalkane-tagged peptides are incubated with HeLa cells expressing HaloTag that is localized 
to the outer membrane of mitochondria, positioned in the cytosol. Upon entry into the cytosol, the 
chloroalkane-tagged peptide binds irreversibly to HaloTag, thereby blocking those HaloTag active 
sites. After washing away unbound peptide, cells are incubated with a chloroalkane-dye which 
quickly penetrates the cells and reacts with the remaining HaloTag sites. After washing away 
unbound chloroalkane-dye, the resulting fluorescence signal is quantified via flow cytometry. The 
signal is inversely proportional to the amount of chloroalkane-tagged peptide that penetrated the 
cell.  
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All peptides were N-terminally tagged with a chloroalkane group and incubated with the 
HaloTag-expressing cells for 4 hours or 24 hours at various concentrations (Figs 4.2a, 4.2b). CP50 
values, derived from a simple IC50 curve fit, indicate the concentration at which 50% of HaloTag 
sites are saturated with ct-peptide after a given incubation time 106. At 4 hours, we observe very 
little penetration of ATSP-7041 into the cytosol while the double-click stapled peptides penetrate 
the cytosol at concentrations 10 µM and above (Fig 4.2a). At 24 hours, all peptides had lower CP50 
values, with the double-click stapled peptides roughly 2- to 4-fold more penetrant than ATSP-
7041. Surprisingly, given its high target affinity but lack of cellular efficacy, pepG exhibits the 
Figure 4.2 CAPA Results 
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highest penetration with a CP50 of 2 µM at 24 hours (Fig 4.2b). These and other peptides largely 
follow a 1st-order penetration rate in time and concentration (S Fig 4.1). Using a simple 1st order 
model, the rate of cytosolic penetration (and associated equilibrium half-life) for pepG is 1.9 hours 
(Table 4.1) (Note that this does not mean it takes this long to saturate the target; rather it is the 
time to theoretically equilibrate with the extracellular concentration.)  
Table 4.1 Cellular Penetration Rates 
Peptide 
Uptake Rate 
Constant 
(1/hr) 
Equilibrium  
Half-Life (hr) 
ct-s-plp[-2] 0.213 3.2 
ct-s-pepG 0.365 1.9 
ct-s-pepC 0.267 2.6 
ct-ATSP-7041 0.084 8.3 
 
The fast cytosolic penetration of pepG was unexpected considering it has reasonable target affinity 
(5 nM) but showed no efficacy in SJSA-1 and LnCAP, even at 10 µM over 5 days. It was also 
unexpected that ATSP-7041 had the lowest penetration rate with a CP50 of 8.6 µM at 24 hours and 
half-life of 8.3 hours—4 fold higher than pepG. Together, these data indicate the peptide with the 
lowest in vitro efficacy paradoxically has the fastest cytosolic penetration while the most 
efficacious peptide had the slowest cytosolic penetration of the series. pepC and plp[-2] both have 
moderate penetration rates with half-lives of 2.6 and 3.3 hours, respectively. The ability to traverse 
the lipid bilayer is often tied to the lipophilicity of a molecule, which is often represented by an 
octanol/water partitioning coefficient. Therefore, we decided to perform additional biophysical 
characterization of the peptides to help explain the cytosolic penetration. 
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4.4.2 Membrane Partitioning 
As discussed in Chapter 2, lipophilicity and charge two of the primary determinants of cell 
membrane permeability for low molecular weight compounds including peptides89. As shown in 
Table 4.2, all of the peptides tested here are negatively charged, having either a -1 or -2 charge.  
Table 4.2 Peptide Sequences and Charges 
Name Sequence Charge 
 X=Azidohomoalanine  
plp-2  Ac-ETFXDLWRLLXEN-NH2 -2 
pepG Ac-GGTFXGYWADLXAF-NH2 -1 
pepC Ac-VCDFXCYWNDLXGY-NH2 -2 
ATSP-
7041 
  Ac-LTFxEYWAQxxSA-NH2 
x1=R8, x2=Cba, x3=S5 -1 
 
Given that there were no positively charged variants in this series with high or moderate binding 
affinity, we could unfortunately not include this in our selection criteria. We therefore focus on 
lipophilicity. Classically, octanol/water partition coefficients are measured for small molecules, 
and computational approaches can be used to predict these values. Experimental measurements of 
octanol/water partitioning coefficients are often limited by sensitivity when dealing with highly 
lipophilic or hydrophilic molecules, and computational tools often fail to accurately represent 
peptides by not accounting for intramolecular interactions such as hydrogen bonds 55,107. 
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Therefore, we used HPLC retention times (e.g. 44,85,108) to compare the lipophilicity of various 
peptides and estimate the logD based on a series of standards (S Fig 4.2). We utilized reverse-
phase HPLC with ammonium acetate buffered water (pH 7.4) and acetonitrile as the mobile phase. 
ATSP-7041 has the highest retention time and apparent logD (3.0), likely due to the high 
abundance of hydrophobic residues and the all-hydrocarbon staple. pepC, pepG and plp[-2] have 
similar apparent logD values of 2.1, 2.2, and 2.3, respectively (Fig 4.3). To characterize the 
peptide/membrane interaction, we next measured peptide/liposome interactions spectroscopically. 
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Figure 4.3 HPLC Retention Times and Apparent LogD 
 
 69 
The lone tryptophan within the peptide sequences enabled spectroscopic measurements of 
peptide interactions with lipid bilayers (liposomes)109. First, intrinsic tryptophan fluorescence was 
measured with increasing concentrations of lipids (liposomes). The environmentally sensitive 
fluorescence peak of tryptophan blue shifts when it moves from a hydrophilic to a hydrophobic 
environment 110. Only ATSP-7041 showed a definitive shift in fluorescence, indicating it is buried 
deep within the lipid bilayer, while pepG showed a slight shift and the other peptides showed no 
detectable change (S Fig. 4.3). To determine if the other peptides were interacting with the 
membrane, acrylamide quenching experiments were conducted. The Stern-Volmer constant (Ksv), 
the slope of normalized fluorescence vs. acrylamide concentration111, was measured in the 
presence or absence of liposomes (Fig 4.4).  Acrylamide, a water-soluble quencher, is unable to 
Figure 4.4 Tryptophan Fluorescence Acrylamide Quenching Plots 
 70 
penetrate hydrophobic environments, so only tryptophan residues not embedded in the membrane 
can be quenched. ATSP-7041 and pepG had the highest Stern-Volmer constant ratios (12.3 and 
8.6, respectively) (Table 4.3), indicating these peptides had the strongest interaction with the 
membrane, followed by plp[-2] and pepC.  
Table 4.3 Stern-Volmer Constants 
Stern-Volmer Constants 
 Peptide Only Peptide + Liposomes ratio 
s-plp[-2] 10.84 2.59 4.2 
s-pepG 30.08 3.50 8.6 
s-pepC 3.63 4.02 0.9 
ATSP-7041 29.97 2.43 12.3 
 
A helical wheel representation of the sequences shows the distribution of hydrophobic and 
hydrophilic residues as well as the hydrophobic moment values 112 computed from the published 
structures of pepC and ATSP-7041 88,104. All peptides have a large hydrophobic face including the 
hydrophobic binding interface of the conserved F, W, and L residues with slight differences in the 
overall number of hydrophilic residues and their locations. pepC and ATSP-7041, having the least 
and most tryptophan acrylamide quenching, respectively, are different in that the all-hydrocarbon 
staple of ATSP-7041 contributes to the lipophilicity of ~3/4 of the residues while the less lipophilic 
linker of pepC contributes to a more evenly split distribution of hydrophilic and hydrophobic 
residues (and resulting high hydrophobic moment). This allows for more aqueous solvent 
interactions and a lower propensity for the tryptophan to partition into the liposomal membrane. 
The deeply membrane embedded ATSP-7041 could potentially slow the transient rate of 
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membrane translocation in the CAPA assay by retaining the peptide. However, these results still 
did not match the rank order of cellular efficacy. 
4.4.3 Protease Stability  
The lack of efficacy from pepG despite its high affinity and efficient cytosolic penetration could 
not be explained by affinity and permeability alone. Therefore, we tested protease resistance as a 
measure of stability inside the cell. Using chymotrypsin as a model protease (2-3 cleavage sites 
per peptide), plp[-2] and pepG completely degraded within minutes in non-stapled form. 
Interestingly, non-stapled pepC was significantly more resilient than other non-stapled peptides, 
likely due to the disulfide loop present within the structure. When stapling with propargyl ether, 
plp[-2] was substantially more resistant, with a half-life of over 70 min, while pepG only modestly 
improved (11.2 min). The bicyclic pepC had a ~440 min half-life under these conditions. For 
comparison, ATSP-7041 did not have detectable degradation at this enzyme concentration before 
autolysis of the enzyme reduced activity. When using a 10-fold higher enzyme concentration, 
ATSP-7041 degraded with a 2 hour half-life, followed by 20 min for pepC and 8 min for plp[-2] 
(Figure 4.5). PepG degraded too quickly to measure under these conditions. The lack of stability, 
despite the high cytosolic penetration and binding affinity of pepG, is consistent with low 
intracellular concentrations and lack of target engagement for this stapled peptide. 
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4.5 Discussion 
In this work, we profiled the in vitro efficacy, cytosolic penetration, lipophilicity/hydrophobicity, 
and protease stability of a series of high affinity MDM2-binding stabilized peptides developed 
through SPEED along with the well-studied clinical lead compound, ATSP-7041. Based on 
affinity alone, we hypothesized that the double-click stabilized peptides tested would have in vitro 
activity. However, only one, pepC, showed efficacy, and this was similar to the potency of ATSP-
7041 in the cell lines tested. As previously discussed, affinity is only one relevant parameter in the 
overall efficacy of a peptide. Our aim was to use subsequent experiments to characterize why the 
other peptides showed no efficacy and to gain general knowledge about the range of 
Figure 4.5 Chymotrypsin Degradation Half-Lives 
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physicochemical properties and cellular kinetics for this series of peptides that enable cell entry 
and efficacy. 
 The affinity of intracellular targeting agents clearly plays a role in efficacy. Given the 
relatively poor cytosolic penetration of stapled peptides, high affinity is likely required given 
anticipated low intracellular concentrations, and we tested several stapled peptides with moderate 
to high affinity . The increased structure of stapled helices can increase target affinity by lowering 
the entropic penalty of binding, and affinity screens often select for more rigid structures, such as 
those containing disulfide bonds 70,113. Helix stabilization increased affinity for the current series 
of peptides, although this is not always true when comparing different sequences 114,115. This can 
be due to complex factors like solvent interactions and entropy/enthalpy compensation 72, where a 
more rigid structure may improve the entropy of binding but reduce the flexibility needed for 
optimal enthalpic interactions (e.g. hydrogen bond angles) and vice versa. ATSP-7041 with its 
sub-nanomolar binding affinity appeared to be the best binder in this series of peptides, as well as 
one of the most helical (44%, data not shown) falling just behind the helicity of plp[-2]. Given that 
the latter has the lowest binding affinity despite being the most helical, it is clear that helicity itself 
does not result in strong binding affinity. Furthermore, the fact that pepG has the lowest helicity 
but 3-fold better binding affinity than plp[-2] may be due to the abundance of glycine residues 
which are often considered ‘helix breakers’ 90. The sequence and linker-dependence play a more 
pronounced role in determining affinity, as others have also shown 6. While both ATSP-7041 and 
pepC had the highest affinity and potency, affinity could not explain the complete lack of efficacy 
for pepG. Therefore, the cytosolic penetration rate was determined for each peptide since 
penetration into the cytosol is a major hurdle for stabilized peptides, and the target, MDM2, resides 
in the cytosol.  
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The CAPA assay provided a quantitative measure of peptide accumulation in the cytosol 
over 4 and 24 hour periods. Because affinity did not explain all the efficacy results, we 
hypothesized that efficacy would track with cytosolic penetration, the major hurdle in delivery for 
intracellular biologics. However, this was surprisingly not the case. All of the double-click 
stabilized peptides had faster apparent cytosolic penetration than the more lipophilic clinical lead 
compound, ATSP-7041. Due to its lipophilicity as exhibited by a high HPLC retention time and 
apparent logD, we expected ATSP-7041 to rapidly partition into the lipid bilayer. However, if a 
molecule inserts too deep in the membrane, it can slow translocation across the lipid bilayer and 
transit into the aqueous cytosolic environment116. In contrast, molecules with moderate 
lipophilicity may have lower membrane partitioning, but this may enable quicker diffusion into 
the aqueous (cytosolic) phase (e.g. from an endosomal compartment). We suspected this was why 
the double-click stabilized peptides had roughly 3 to 4-fold faster penetration rates than ATSP-
7041. To probe this hypothesis and determine the mechanistic behavior of peptides interacting 
with lipid bilayers, we utilized liposomes as a proxy for cell membranes. Taking advantage of the 
fact that all these peptides have a conserved W23 residue, we measured tryptophan fluorescence 
quenching in the presence of POPC liposomes and acrylamide. ATSP-7041 rapidly partitioned 
into the liposomal bilayer as evidenced by the dramatic leftward shift in fluorescence in the 
presence of liposomes, a phenomenon not exhibited by the other peptides. Furthermore, the Stern-
Volmer constants resulting from acrylamide quenching studies show that the tryptophan residue 
in ATSP-7041 is heavily shielded by the liposomal bilayer. This result supports our hypothesis 
regarding rapid membrane partitioning and explains the trends seen in the CAPA assay: the highly 
lipophilic sequence and all-hydrocarbon staple enable deeper penetration of the tryptophan into 
the lipid bilayer core as seen in the helical wheel diagram. However, as others have found, this 
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partitioning can sequester the peptide within the membrane, slowing transport across the bilayer 
116. In contrast, the more hydrophilic double-click stabilized peptides did not reside as deep within 
the lipid bilayer. Notably, pepG has an acrylamide quenching Stern-Volmer constant ratio that is 
the second highest after ATSP-7041. Interestingly, this peptide has the fastest cytosolic penetration 
rate while ATSP-7041 has the slowest. We hypothesize that in this series of peptides, pepG may 
have the most balanced lipophilicity to achieve efficient cell entry—lipophilic enough to partition 
rapidly into the membrane but not too lipophilic that it gets trapped. However, the fast cytosolic 
penetration of this high affinity peptide runs counter to the observed lack of efficacy. Therefore, 
we had to look for mechanisms beyond the ability to reach the site of action and bind the target 
with high affinity to explain cellular potency.   
Up until this point, we had not explicitly measured degradation as a possible contributor to 
efficacy among the stapled peptides. Degradation rates are relevant in vitro, with the presence of 
lysosomal and cytosolic proteases, and even more-so in vivo, where proteases in serum and 
digestive fluids could degrade a peptide therapeutic before even reaching the target cells. We 
therefore conducted a protease digest assay, directly comparing degradation of each peptide by 
chymotrypsin, chosen for its promiscuity in this series of peptides. These results showed that 
ATSP-7041 is extremely stable in comparison to the other peptides with a 128.8 min half-life at a 
high chymotrypsin concentration, followed by pepC (19 min), plp[-2] (7.8 min) and pepG which 
degraded near-immediately. Anecdotally, ATSP-7041 also showed less day-to-day variability in 
cellular assays, likely due to this extremely high stability. 
In contrast to cytosolic penetration rates, the degradation rates seen here correlate well with 
the efficacy results. plp[-2] has the greatest increase in helicity upon stapling, but it is significantly 
less stable than ATSP-7041 and pepC. Even with efficient cytosolic penetration, modest stability 
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inside the cell and moderate affinity of plp[-2] are not enough for cellular efficacy. pepG has high 
affinity and the highest apparent cytosolic penetration rate, but it is the least stable, likely leading 
to rapid degradation in lysosomes and/or the cytosol, low intracellular concentrations, and little 
target engagement. Rapid degradation could result in released chloroalkane tag entering the cytosol 
(rather than intact peptide), increasing the apparent cell penetration rate as measured by CAPA106. 
However, the rate and magnitude of proteolysis did not match the CAPA results (e.g. pepG has 
less than two-fold faster cell penetration but degrades almost 40 times faster), indicating this 
artifact wasn’t the main source of CAPA signal, and may not have contributed to the apparent rates 
of cell penetration. Regardless of the membrane uptake rate, the peptide must remain intact prior 
to entering the cytosol for efficacy. In comparison with pepC, ATSP-7041 has slower cytosolic 
penetration, but its extremely high stability and ~2-fold lower Kd enable high intracellular 
accumulation and target binding. The high helicity, alpha carbon methyl groups, and non-natural 
amino acids likely all contribute to this stability. pepC, though much less helical (28% versus 
44%), has an intrahelix disulfide bond, likely contributing to its protease resistance in oxidizing 
environments. It is unclear how quickly the disulfide is reduced in the cytosol, but surface display 
measurements indicate only a 2-fold drop in affinity without the disulfide bond88. Together, its 
high affinity, efficient cytosolic penetration, and good protease stability enable on-target efficacy.  
 
4.6 Conclusions 
These results, summarized in Figure 4.6, highlight the rate of protease degradation as a key design 
parameter in stabilized peptide design. While affinity and cytosolic penetration are critical features 
and often the focus of stabilized peptide development, intracellular stability (beyond just stapled 
versus linear peptides) can play an equally important role. In the compounds examined here, high 
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affinity was pre-selected, so affinity did not play a distinguishing role. The cytosolic delivery rate 
was also fairly high for this series of stapled peptides. The binding interface of the MDM2 binding 
peptides is lipophilic, with hydrophilic side chains on the opposite face likely contributing to 
aqueous solubility. The resulting amphiphilicity likely contributed to the efficient cytosolic 
penetration, consistent with reports by others 42,89. With similar apparent cytosolic penetration rates 
and target affinity, protease stability had the greatest correlation with cellular efficacy in this 
peptide series. These rates are all interdependent – penetration vs. degradation determine 
intracellular concentration while affinity determines target engagement. Based on this data, it is 
possible for agents with lower affinity or slower cell penetration to be more effective in vitro. 
Therefore, all these rates need to be considered together to identify the most effective compound 
for cellular efficacy. 
 
Figure 4.6 Summary of Physicochemical Properties 
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4.7 Experimental Methods 
4.7.1 Synthesis, Purification and Stabilization 
Solid phase peptide synthesis and double-click stabilization of i,i+7 diazido peptides were carried 
out as previously described 88. Solid phase synthesis was done using a CEM Liberty Blue 
Microwave Peptide Synthesizer. Rink amide resin and Fmoc amino acids were purchased from 
ChemPep Inc. All other reagents were purchased from Sigma Aldrich. After cleavage from resin, 
purification and lyophilizing, peptides were stabilized in 1:1 water:tert-butanol via copper 
catalyzed azide alkyne cycloaddition with propargyl ether. 
Characterization via electrospray ionization mass spectrometry (ESI-MS) and HPLC purities are 
reported in Table 3.3. 
ATSP-7041 was provided by the University of Michigan Proteomics and Peptide Synthesis Core. 
 
4.7.2 Chloroalkane Penetration Assay (CAPA)  
Cell culture and maintenance 
The cells used in CAPA were grown in DMEM media with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, and 1 µg/mL of puromycin in tissue culture treated T75 flasks. Cells were 
passaged at confluency, every 2-3 days.  
 
Ct-Peptide Synthesis 
Peptides were synthesized via solid phase peptide synthesis as described but without an n-terminal 
acetyl cap. Post-synthesis, peptides were mixed on resin with chloroalkane tag (2.5 equiv), PyBOP 
(2.5 equiv) and DIPEA (7 equiv) for 1 hour with nitrogen bubbling. Peptides were then washed 
with DCM and cleaved as previously described. 
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Ct-ATSP-7041 was synthesized and provided by the University of Michigan Proteomics and 
Peptide Synthesis Core. 
 
CAPA Assay 
The chloroalkane penetration assay was performed as described previously 105. Briefly, HeLa cells 
that stably express a cytosolically oriented HaloTag-GFP fusion protein were seeded in a 96-well 
plate to obtain 60-80% confluency at the start of the experiment. The growth media was aspirated 
from the adhered cells and replaced with 100 µL of optiMEM culture media supplemented with 
10% FBS. Serial dilutions of chloroalkane-labelled peptides were performed in optiMEM 
supplemented with 10% FBS in a separate 96-well plate. Solutions were made at 5x concentration, 
as 25 µL of these peptide solutions were subsequently added to the cells and incubated for 24 hr 
at 37 ºC. After incubation, the media was aspirated and cells were washed with 80 µL fresh 
optiMEM for 15 min at RT. OptiMEM was removed and replaced with 50 µL of 5 µM 
chloroalkane-labelled tetramethylrhodamine (ct-TMR) in optiMEM. Cells were incubated with ct-
TMR for 15 min at RT and then washed with fresh optiMEM for 30 min at RT. Media was replaced 
with 40 µL 0.05% clear trypsin, diluted from 0.5% in PBS, and incubated for 5 min at 37 ºC. Cells 
were resuspended in 180 µL PBS and analyzed by flow cytometry, measuring the red fluorescence 
of 5,000 cells per sample. Raw values were normalized to background fluorescence of the cells 
(minimum) and the red fluorescence of cells that were treated only with ct-TMR (maximum). Data 
was curve-fit to give CP50 values in KaleidaGraph using a log(inhibitor) vs. response variable 
slope model.  
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Internalization Rate Modeling 
CAPA data was fit to following ordinary differential equations: 𝑑𝑐()𝑑𝑡 = 𝑘()𝑐*+, − 𝑘()𝑐() − 𝑘!-.𝑐() 𝑑𝑐/01*,0.𝑑𝑡 = −𝑘23)𝑐()𝑐/01*,0. + 𝑘!-.𝑐/01*,0."4-4,(!- 𝑑𝑐/01*,0."4-4,(!-𝑑𝑡 = 𝑘23)𝑐/01*,0.𝑐() − 𝑘!-.𝑐/01*,0."4-4,(!- 
Where the variables stand for: 𝑐(), concentration of peptide inside the cell; 𝑐*+,, concentration of 
peptide outside the cell; 𝑐/01*,0., the concentration of HaloTag inside the 
cytosol;	𝑐/01*,0."4-4,(!-, the concentration of HaloTag -peptide reacted inside the cell; 𝑘(), the 
rate of peptide entering the cell (1/sec); 𝑘23), the rate of HaloTag -chloroalkane peptide reaction 
(1/µM/sec); 𝑘!-., the rate of HaloTag turnover inside the cell (1/sec). The following conditions 
are applied to the system: 𝑐*+, is constant, since the amount of peptide entering cells does not 
deplete the peptide added to the wells; the kinetics of the reaction between HaloTag and 
chloroalkane are dependent on the concentration of each in a second order fashion; the amount of 
HaloTag inside the cell at any point is constant – for each mol of HaloTag or HaloTag -peptide 
degraded, there is a mol of HaloTag synthesized. Data from Peraro et al. (2018)117 were fit to these 
equations using Matlab’s fminsearch function for validation. Data fitting curves for the peptides 
discussed in this work are shown in Figure 4.5. Half-lives for the peptides are calculated from the 
uptake rate: 
 𝑡5/6 = ln(2) /𝑘() 
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4.7.3 Chymotrypsin Digest  
To measure resistance to protease degradation, stabilized and non-stabilized peptides were 
incubated with chymotrypsin at 5ng/uL and 50ng/uL in PBS. Peptides were first diluted to 100µM 
in PBS before adding the enzyme and incubating at 37ºC. After each time point, samples were 
flash-frozen in liquid nitrogen to stop digestion and stored at -80ºC until analysis. Samples were 
analyzed by reverse-phase HPLC at 214nm and 280nm wavelengths. The fraction of intact peptide 
remaining at each time point was quantified by the area under the curve of the intact peptide peak 
on the chromatograph. Exponential decay curves were fit in GraphPad Prism v.8. 
4.7.4 HPLC Retention Time  
Peptides and standards were run on a reverse-phase HPLC column in mobile phase containing 
50mM ammonium acetate at pH 7.4 in water and acetonitrile with a gradient of 10-95% over 50 
minutes. Standards were chosen based on a previously published method for estimating logD from 
HPLC retention time 85 (S Fig. 4.2). All standards used here have a logD(pH 7.4) greater than 0 as 
measured by ChemAxon MarvinSketch software and are acidic (with the exception of Cyclosporin 
A which is a neutral cyclic peptide) to best reflect the peptides analyzed, all of which are acidic 
and mostly water insoluble. A standard curve was generated and apparent logD’s were calculated 
from the standard curve equation. 
4.7.5 Liposomal Experiments 
Preparation of Liposomes 
About 2mg of dried POPC (1-palmitoyl-2-oleoyl-glycero-3-phosphocholine) powder was 
dissolved in chloroform:methanol (3:1) in a round bottom flask. The solvent was then evaporated 
under a stream of nitrogen gas. This resulted in the formation of a thin film on the sides of the flask 
which was then lyophilized overnight to completely remove any trace of the solvents. The dried 
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lipid film was then dissolved in PBS buffer (pH 7.4). The mixture was sonicated in a water bath 
for 10 minutes. Multilamellar vesicles formed from sonication were extruded through 50 nm 
membranes and the size of the liposomes was confirmed by dynamic light scattering (DLS). 
Prepared liposomes were stored at 4°C until use. 
 
Fluorescence studies 
All of the fluorescence studies were carried out in a Cary Eclipse fluorescence spectrophotometer 
(Varian, Inc.) in phosphate buffered saline, PBS (pH 7.4). 
 
Intrinsic tryptophan fluorescence and acrylamide quenching 
The localization of stapled peptides in a lipid environment was probed by using tryptophan 
fluorescence. 5 μM of peptide was dissolved in 200 μl of PBS buffer and the emission spectrum 
from tryptophan fluorescence was acquired (from 300 to 400 nm) in the free state with excitation 
at 295 nm. Each peptide sample was titrated with increasing concentrations of POPC lipids, and 
the fluorescence emission was recorded from 300 to 400 nm. Fluorescence quenching of the 
tryptophan residue was carried out by adding increasing concentrations of acrylamide from a 2M 
stock solution to a solution containing only peptide and also to a peptide+liposome solution. The 
Stern-Volmer constant (Ksv) values were then calculated using F0/F = 1 + Ksv [Q], where F0 and F 
are the fluorescence intensities before and after the addition of quencher and [Q] is the quencher 
concentration. 
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4.8 Supplemental Figures 
 
S Figure 4.1 CAPA Uptake Rate Data Fits 
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Standard 
Compound Retention Time logD (pH 7.4) 
4-methoxyphenol 12.333 1.51 
phenol 12.752 1.67 
2,4,6-trichlorophenol 21.03 2.1 
4-phenyl phenol 25.036 3.32 
Cyclosporin A 37.668 3.35 
 
          
Peptide Retention Time 
Apparent 
LogD (pH 
7.4) 
plp[-2] 
linear 22.301 2.43 
stapled 20.478 2.29 
pepG 
linear 21.256 2.35 
stapled 19.584 2.22 
pepC 
linear 19.91 2.25 
stapled 18.085 2.11 
ATSP-7041 hydrocarbon stapled 29.756 3.00 
 
S Figure 4.2 HPLC Retention Time LogD Standards  and Peptide Retention Times 
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S Figure 4.3 Tryptophan Fluorescence Quenching Curves 
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Chapter 5 Conclusions and Future Directions 
 
5.1 Summary of Work and Concluding Remarks 
This dissertation explored the key properties that determine the efficacy of stabilized peptides for 
intracellular drug targets. Chapter 1 explored the world of peptide-based therapeutics for 
intracellular targets with a focus on stapled peptides and the work that has been previously done 
to make these molecules more cell-penetrant and stable in physiological conditions. This 
literature review exposed both a common theme in peptide-based drug development—the 
importance of membrane permeability and the physicochemical properties that promote it—and 
the lack of successful intracellular stapled peptide drug candidates that have yet emerged in the 
clinic. The goal of this work was therefore to contribute to this field by elucidating the main 
contributors to cellular uptake and ultimately, efficacy of stapled peptides. We began by studying 
two important properties that are widely considered to be key in membrane permeability of 
molecules—lipophilicity and charge (Chapter 2). We then chose a series of MDM2-inhibiting 
stabilized peptides discovered through bacterial-surface display and measured their in-solution 
binding affinities and in vitro efficacies to identify early stage lead compounds for further study 
and identification of favorable physicochemical properties (Chapter 3). Lastly, in Chapter 4, we 
took the highest affinity and most efficacious peptides in the series and measured their cellular 
penetration rates, membrane interactions, and proteolytic stabilities. The results of this study 
showed that in the series of peptides tested, protease stability was the differentiator for efficacy.  
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Until this point, many have engineered stabilized peptides with various features (linker 
chemistries, non-natural amino acids, etc.)6,14,41,63,89,118 and by various methods (phage display, 
bacterial surface display, computational simulations, etc.)88,113,119,120 but without an explicit focus 
on simultaneously quantifying the most important design parameters for efficacy. Nonetheless, 
previous literature has revealed a great deal about what those important parameters are. A 
general consensus in the field of stabilized peptides is that intracellular delivery is a limiting 
factor in achieving efficacy121. Furthermore, studies on small molecules and beyond rule-of-five 
molecules have shown that cellular penetration is enhanced with increased lipophilicity (Chapter 
1). Stabilized peptide literature has also shown that positive charge helps enhance cell entry and 
many have used this as a means of increasing efficacy (Chapter 1). These observations motivated 
Chapter 2 in which we specifically sought to study the impact of lipophilicity and charge on 
cellular entry in a controlled manner, using one peptide sequence (plp[-2]) and making minimal 
residue modifications between experimental conditions. Leveraging the double-click 
stabilization technique allowed us to alter lipophilicity via the stabilizing linker while 
substituting glutamic acid residues with glutamine provided a means of increasing charge 
without drastic sequence modifications. As a result, we created a series of 9 fluorescently labeled 
stabilized peptides with distinct lipophilicity and charge combinations. Results showed that even 
incremental increases in charge caused a significant increase in uptake, with neutral and single 
positive charge being more favorable than a single negative charge. Furthermore, while increased 
lipophilicity is a useful tool to achieving cellular uptake, results showed that molecules that are 
too lipophilic can be less cell penetrant (and this was also observed later on in Chapter 4, 
although uptake mechanisms may be different in these two instances). Although these findings 
showed us the effects that charge and lipophilicity can have on uptake, they didn’t directly relate 
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to efficacy, as the peptide sequence used is not efficacious and was used only as a proof of 
concept. We therefore proceeded in Chapter 3 to select peptides that already have efficacy such 
that we could analyze their physicochemical properties and determine what differentiates 
peptides with and without efficacy.   
The peptides analyzed in Chapter 3 were discovered via SPEED, a bacterial surface 
stabilized peptide display technique developed by my colleague, Tejas Navaratna. We identified 
two peptides with single digit nanomolar binding affinities (Kd), pepG and pepC, which we 
tested for efficacy alongside plp[-2] and ATSP-7041—an all-hydrocarbon stapled peptide with 
picomolar binding affinity that is the precursor to another peptide currently in clinical trials. A 
cell viability assay showed that pepC has similar efficacy to ATSP-7041 while pepG, like plp[-
2], has no efficacy. Given the lack of efficacy with pepG, despite its high binding affinity, we 
quantified additional properties that could impact efficacy. This was the focus in Chapter 4. In 
this chapter, we measured the apparent logD, cytosolic penetration rate, membrane interaction, 
and protease degradation rate of pepC, pepG, plp[-2] and ATSP-7041. We ultimately found that 
despite having the fastest cytosolic uptake rate, pepG was the least protease stable. We therefore 
concluded that in this series of peptides, binding affinity and degradation rate, not cellular uptake 
rate, played a dominant role in efficacy. Although ATSP-7041 was the slowest to penetrate the 
cytosol, it was by far the most stable peptide. Its stability in conjunction with its high binding 
affinity compensated for the slower uptake relative to the other peptides. Likewise, pepC, being 
the second most stable and having the second best binding affinity, was the second most 
efficacious. A visual summary of the contributions of each measured physicochemical property 
is shown in Fig 4.6. 
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The greatest takeaway from the sum of this research is the fact that the design of 
stabilized peptide therapeutics, specifically those with intracellular targets, must 
comprehensively and quantitatively take into account membrane permeability, binding affinity 
and intracellular stability. There is much room for advancements in the field, including a general 
design approach that takes into consideration the relevant rates that determine efficacy, not just 
in vitro but also in vivo, addressing the challenges that will be met from the molecular level to 
the systemic level (Fig 5.1). This work is the first step in applying a more wholistic methodology 
in assessing what leads to an efficacious peptide. Most of the focus in stabilized peptide 
discovery is iterative optimization to increase binding affinity. Although binding affinity is an 
important feature, it is necessary to consider it in context with other parameters, as was the case 
with pepG. Given that this work was only the first step in addressing this, there is much future 
work that can be done.   
 
Figure 5.1 Multiscale Pharmacokinetic Challenges of Therapeutic Peptides 
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5.2 Future Work 
5.2.1 Profiling Other Peptide Types and Model Development 
The focus of this work has been on stabilized peptide inhibitors of MDM2; however, there are 
other emerging classes of peptides engineered to target intracellular PPIs. These include knottins 
which are plant-derived peptides containing three disulfide bonds, forming a “knotted” structure. 
Cyclotides are a subclass of knottins, featuring a head-to-tail cyclized backbone. They have been 
shown to be highly stable and cell-penetrant despite their large size and molecular weights (~30-
40 residues)122,123. Researchers from the Camarero group have engineered an MDM2 inhibiting 
cyclotide, MCo-PMI (based off of the natural cyclotide MCo-TI-I), with efficacy in vivo and 
strong tumor growth inhibition in vivo49. This cyclotide features a helical portion with the key 
MDM2-binding residues found in stabilized peptide MDM2-inhibitors, however this helical 
motif lies within a larger cyclotide backbone, thereby maintaining the stability and cell 
permeability benefits provided by the original cyclotide. They have also shown that cyclotides 
can be used as a peptide drug development scaffold for generating bacterial libraries that can be 
screened against protein targets124. Given the uniqueness of cyclotides as large peptides with 
measurable membrane permeability and protease stability as well as the potential they have as 
drug development scaffolds, cyclotides are well-suited candidates for profiling the most 
important properties for efficacy. Furthermore, it would be useful to have a model that takes into 
account the rates associated with these properties (i.e. binding affinity, cell penetration, and 
degradation rate) and predicts efficacy. Currently, measurements of binding affinities and 
cellular penetration rates are achievable as shown in Chapters 3 and 4. Some knottins are also 
FDA-approved and can be purchased123,125, therefore they can be tested in the CAPA assay to get 
penetration rates. The only parameter lacking is a degradation rate measurement method that is 
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reflective of intracellular degradation. Controlled single protease assays like what was done with 
chymotrypsin in Chapter 4 are useful for pushing the limits of degradation by exposing the 
peptides to high concentrations of a protease with several cleavage sites on the peptide. 
Additionally, others have shown that specifically chymotrypsin stability correlates with serum 
stability126. Furthermore, although chymotrypsin has specific cleavage sites that may be different 
than those of proteases inside the cell, resistance to protease degradation is both residue and 
conformation dependent. The overall structure of a peptide, especially when influenced by 
backbone modifications such as alpha-carbon methylation127 as in ATSP 7041 or a disulfide 
bond128 as in pepC, can have more global effects on protease resistance, meaning that these 
effects may correlate to other proteases more generally. Nonetheless, the absolute peptide 
degradation rate in the presence of chymotrypsin at an arbitrary concentration is not directly 
translatable to a model that aims to predict efficacy (IC50) since it is the intracellular degradation 
rate that affects the intracellular concentration of peptide. Therefore, the absolute rate in the 
context of proteases and concentrations inside the cell are the most relevant. A cellular method, 
such as an assay in which cells are treated with peptide, lysed, and intact peptide is detected via 
LC-MS89, could provide this absolute rate. Since LC-MS requires a substantial amount of 
material, equipment, and optimization, another option is an HPLC-based detection method in 
which the peptides of interest are fluorescently labeled. One of my colleagues, Haolong Huang, 
has already succeeded in synthesizing and conjugating pepC variants with a C-terminal lysine to 
two different fluorophores (via SPPS and NHS ester amine chemistry).  Furthermore, another 
colleague, Marshall Case, has already succeeded in building a model that outputs cellular 
penetration rates based on the CAPA results. That model was used to estimate penetration rates 
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in Chapter 4. Therefore, some preliminary work is already underway that could lead to the 
development of a model that would predict efficacy based on those three rates. 
 While acknowledging the shortcomings of a model that predicts cellular efficacy using 
single protease degradation data, preliminary results in conjunction with our measured binding 
affinities and cytosolic penetration rates provide insight into the potential of such a model. In a 
simplified cellular compartmental model, the cytosolic penetration rate and degradation rate 
determine intracellular concentration of the peptide while the binding affinity determines target 
occupancy. In order to calculate the target occupancy at IC50, we used the reported IC50s and 
binding affinities of Nutlin3a129 (a small molecule MDM2-inhibitor), as well as the assumption 
that intracellular delivery is not limiting for this small molecule, to calculate a target occupancy 
(fraction bound) of 95% at the IC50 using the equation below. We then used that occupancy to 
calculate the effective concentration of peptide inside the cytosol for each peptide using its 
binding affinity and the equation below. 
𝑓 = 	 𝐶(),207-11+102𝐶(),207-11+102 + 𝐾! 𝑓 = 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛	𝑏𝑜𝑢𝑛𝑑	 𝐶(),207-11+102 = 𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟	(𝑐𝑦𝑡𝑜𝑠𝑜𝑙𝑖𝑐)	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	 𝐾! = 	𝑏𝑖𝑛𝑑𝑖𝑛𝑔	𝑎𝑓𝑓𝑖𝑛𝑖𝑡𝑦 
 
 In order to relate the chymotrypsin degradation rate to an intracellular degradation rate, we 
solved the following mass balance equation for stabilized pepC in SJSA1 cells using our 
experimental IC50, kin, and previously calculated intracellular concentration and then calculated 
degradation rates for all other peptides by normalizing to the calculated pepC degradation rate. 
Therefore, we used pepC as our reference point for the absolute intracellular degradation rate and 
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scaled the other peptide’s rates based on relative chymotrypsin stability. The results of this 
simple model are shown in Figure 5.2. 𝑘()(𝐼𝐶50) = 	𝑘!-.(𝐶(),207-11+102) 𝑘() = 𝑖𝑛𝑡𝑒𝑟𝑛𝑎𝑙𝑖𝑧𝑎𝑡𝑖𝑜𝑛	𝑟𝑎𝑡𝑒	𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 𝑘!-.	 = 𝑑𝑒𝑔𝑟𝑎𝑑𝑎𝑡𝑖𝑜𝑛	𝑟𝑎𝑡𝑒	𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡	 𝐶(),207-11+102 = 𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟	𝑐𝑜𝑛𝑐𝑒𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑜𝑓	𝑑𝑟𝑢𝑔 
 
 Even with the simplifications and assumptions made, the computational IC50s measured 
from this model are very close to the experimental values with deviations of less than 50% across 
all peptides in both cell lines. Note that concentrations in the experimental assay went up to only 
10µM, as denoted with the dotted line. Therefore, IC50s higher than that were not captured 
experimentally. Nonetheless, this is an encouraging result that signals the possibility of 
developing a true robust model using cellularly relevant degradation rates.  
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5.2.2 Chemical Modification of pepC  
Another opportunity for future work is further engineering pepC to increase its stability and 
binding affinity, making it a better candidate for in vivo efficacy studies. Although the disulfide 
bond is a unique feature that undoubtedly provides more stability and may be the primary reason 
why pepC is the most stable of the SPEED-derived peptides, disulfide bonds are reduced in 
cellular conditions (in vitro) and are at even greater risk of reduction in vivo. This could be 
remedied by replacing the disulfide bond with a more stable linkage, such as a thioether linkage. 
Preliminary attempts have been made to achieve this through substituting one of the cysteine 
residues with the non-natural amino acid vinyl glycine and performing the thioether chemistry 
on-resin, however we have not yet had success incorporating vinyl glycine during synthesis. 
However, there are other potential chemical linkages that can be used and other chemistries that 
can be explored. 
 Another enhancement that could be made to pepC is alpha-methylation of the alpha-
carbons on the non-natural amino acids. This is a feature that is included in the non-natural 
stapling amino acids of ATSP-7041 and has helix inducing properties which could enhance both 
binding affinity and proteolytic stability89. Furthermore, D-amino acid substitution, which is 
typically considered to be helix-breaking and to disrupt binding for key amino acids, has been 
shown in the case of Trp7 in an MDM2-binding ATSP-7041 derivative to maintain binding. D-
amino acid substitution can be useful in increasing proteolytic stability as well since proteases do 
not recognize those amino acids. These modifications work only on a case by case basis, so care 
will need to be taken to ensure that they are not made at the expense of strong MDM2 binding 
affinity even if proteolytic stability is improved. If both are improved with any of these 
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modifications, the resulting variant should be fully profiled as was done in Chapter 4 in order to 
get a wholistic assessment of the peptide’s properties after chemical alteration.  
5.2.3 In vivo studies 
My final recommendation for future work is to perform in vivo studies with pepC and the 
chemically modified pepC. In vitro cell viability is only the first step in assessing the efficacy of 
a drug, and as depicted in Figure 5.1, there are many challenges faced in vivo before the peptide 
can even reach the target. PepC in its current state may be rapidly cleared and degraded in vivo 
given its moderate lipophilicity (compared to ATSP-7041) and the lack of non-natural amino 
acids and backbone modifications that could help it evade proteolysis. However, these rates 
should be quantified to determine the current pharmacokinetic liabilities. To do this, pepC can be 
conjugated to a dye and injected into mice to monitor clearance, the amount intact after 
clearance, and distribution. Dye conjugation will affect the distribution of the peptide, therefore 
clearance rate and fraction of intact non-labeled peptide can be quantified with LC-MS. 
However, using a dye-conjugated peptide will provide a means to measure localization of the 
peptide within tissue, cellular, and subcellular length scales. As previously mentioned, one of my 
colleagues has already created dye-conjugated pepC variants that can be used to perform these 
experiments. They should, however, be done in parallel with ATSP-7041 as a point of reference, 
therefore a corresponding dye-conjugated version will need to be synthesized and tested. If any 
of the pepC chemical modifications discussed in the previous section are successful in increasing 
binding affinity and protease stability, that variant should also be tested in vivo. 
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